

1 **Human germline biallelic complete NFAT1 deficiency causes the triad**  
2 **of progressive joint contractures, osteochondromas, and**  
3 **susceptibility to B cell malignancy**

4 Mehul Sharma<sup>1,2</sup>, Maggie P. Fu<sup>3,4†</sup>, Henry Y. Lu<sup>1,2†</sup>, Ashish A. Sharma<sup>5</sup>, Bhavi P. Modi<sup>1</sup>,  
5 Christina Michalski<sup>1,2</sup>, Susan Lin<sup>1</sup>, Joshua Dalmann<sup>1</sup>, Areesha Salman<sup>1</sup>, Kate L. Del  
6 Bel<sup>1</sup>, Meriam Waqas<sup>1</sup>, Jefferson Terry<sup>6</sup>, Audi Setiadi<sup>6</sup>, Pascal M. Lavoie<sup>1,2</sup>, Wyeth W.  
7 Wasserman<sup>3,7</sup>, Jill Mwenifumbo<sup>3</sup>, Michael S. Kobor<sup>3,4,7</sup>, Anna F. Lee<sup>6</sup>, Anna Lehman<sup>3</sup> on  
8 behalf of the CAUSES Study, Sylvia Cheng<sup>1</sup>, Anthony Cooper<sup>9</sup>, Millan S. Patel<sup>3</sup>, Stuart  
9 E. Turvey<sup>1,2</sup>

10 <sup>1</sup>Department of Pediatrics, BC Children's Hospital, The University of British Columbia,  
11 Vancouver, British Columbia, Canada

12 <sup>2</sup>Experimental Medicine Program, Faculty of Medicine, The University of British  
13 Columbia, British Columbia, Canada

14 <sup>3</sup>Department of Medical Genetics, BC Children's Hospital Research Institute, University  
15 of British Columbia, Vancouver, British Columbia, Canada

16 <sup>4</sup>Genome Science and Technology Program, Faculty of Science, The University of  
17 British Columbia, Vancouver, British Columbia, Canada

18 <sup>5</sup>Department of Pathology, Emory University, Atlanta, GA, USA

19 <sup>6</sup>Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver,  
20 British Columbia, Canada

21 <sup>7</sup>Centre for Molecular Medicine and Therapeutics, Vancouver, British Columbia, Canada

22 <sup>8</sup>Department of Orthopaedics, Faculty of Medicine, University of British Columbia

23 <sup>†</sup>These authors contributed equally.

24

25

26 **Correspondence to:** Stuart E. Turvey, MBBS, DPhil, FRCPC  
27 BC Children's Hospital  
28 950 West 28<sup>th</sup> Avenue  
29 Vancouver, BC, V5Z 4H4, Canada  
30 Phone: 604 875 2345 ext. 5094  
31 Email: [sturvey@cw.bc.ca](mailto:sturvey@cw.bc.ca)

32

33 **Word Count:** 4000

34 **Abstract:** 150

35

36 **Acknowledgements:** This work was supported by grants from the Canadian Institutes  
37 of Health Research (PJT 178054) (S.E.T.), Genome British Columbia (SIP007) (S.E.T.),  
38 and BC Children’s Hospital Foundation. S.E.T. holds a Tier 1 Canada Research Chair in  
39 Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology.  
40 M.S. is supported by a CIHR Frederick Banting and Charles Best Canada Graduate  
41 Scholarships Doctoral Award (CGS-D) and University of British Columbia Four Year  
42 Doctoral Fellowship (4YF). H.Y.L. is supported by a CGS-D, 4YF, Killam Doctoral  
43 Scholarship, Friedman Award for Scholars in Health, and a BC Children’s Hospital  
44 Research Institute Graduate Studentship. Investigators in the CAUSES Study include:  
45 Shelin Adam, Nick Dragojlovic, Christèle du Souich, Alison M. Elliott, Anna Lehman,  
46 Larry Lynd, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M.  
47 Friedman. We would like to acknowledge Navdeep Sangha at Thomas Jefferson  
48 University Hospital for providing his expertise in B cell lymphomas. We would also like  
49 to acknowledge the histology labs at BC Children’s Hospital and BC Cancer for their  
50 assistance in histological and immunohistochemistry, and the Biomedical Research  
51 Centre Sequencing Core (BRC-Seq) for their assistance with RNA-Sequencing and  
52 processing.

53

54 **ABSTRACT**

55 Discovery of humans with monogenic disorders has a rich history of generating new  
56 insights into biology. Here we report the first human identified with complete deficiency  
57 of nuclear factor of activated T cells 1 (NFAT1). NFAT1, encoded by *NFATC2*, mediates  
58 calcium-calcineurin signals that drive cell activation, proliferation, and survival. The  
59 patient is homozygous for a damaging germline *NFATC2* variant  
60 (c.2023\_2026delTACC; p.Tyr675Thrfs\*18) and presented with joint contractures,  
61 osteochondromas, and B cell lymphoma. Absence of NFAT1 protein in chondrocytes  
62 caused enrichment in pro-survival and inflammatory genes. Systematic single-cell-omic  
63 analyses revealed an environment that promotes lymphomagenesis with accumulation  
64 of naïve B cells (with oncogenic signatures - *MYC*, *JAK1*), exhausted CD4<sup>+</sup> T cells,  
65 impaired T follicular helper cells, and aberrant CD8<sup>+</sup> T cells. This work highlights the  
66 pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with  
67 NFAT1 deficiency, and further define detrimental effects a long-term use of calcineurin  
68 inhibitors.

## 69 INTRODUCTION

70 Intracellular calcium signaling orchestrates a diverse range of critical physiological and  
71 immunological processes, including lymphocyte activation, differentiation, and effector  
72 function<sup>1, 2</sup>. T cell receptor (TCR) or B cell receptor (BCR) engagement activates  
73 phospholipase C (PLC), generating inositol-1,4,5-triphosphate (IP<sub>3</sub>), which, in turn,  
74 activates IP<sub>3</sub> receptors and creates an influx of Ca<sup>2+</sup> from the endoplasmic reticulum  
75 into the cytosol<sup>2</sup>. Free Ca<sup>2+</sup> is subsequently bound by calmodulin, resulting in a  
76 conformation change that promotes binding of the serine/threonine phosphatase  
77 calcineurin<sup>3, 4</sup>. This calmodulin-calcineurin interaction activates an array of transcription  
78 factor families, including the nuclear factor of activated T cells (NFAT) family. This  
79 family consists of five members: NFAT1 (NFATc2, NFATp), NFAT2 (NFATc1, NFATc),  
80 NFAT3 (NFATc4), NFAT4 (NFATc3, NFATx) and NFAT5<sup>5</sup>. These proteins contain an N-  
81 terminal transactivation domain (TAD), a regulatory NFAT homology region (NHR), a  
82 DNA-binding domain (REL-homology domain, [RHD]) and a carboxy-terminal domain.  
83 Activation of NFAT1-4 is dependent on calcineurin-mediated dephosphorylation of the  
84 NHR, which exposes a nuclear localization signal and leads to NFAT translocation to be  
85 nucleus and transcriptional regulation<sup>5, 6, 7, 8, 9, 10, 11, 12</sup>.

86 Originally discovered in activated T cells as a protein complex that binds the interleukin-  
87 2 (IL-2) promoter<sup>13</sup>, our understanding of the NFAT family has grown remarkably over  
88 the past few decades. It is now appreciated that NFATs have a role in the differentiation  
89 and activation of many T helper subsets, including T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17, T follicular helper  
90 cells (T<sub>FH</sub>), and T regulatory cells (Tregs)<sup>14, 15</sup>. NFATs are also expressed by and have a  
91 function in other immune cells including B cells<sup>16</sup> and dendritic cells<sup>17</sup>, as well as in non-  
92 immune cells, such as cartilage cells<sup>18, 19, 20</sup>, adipocytes<sup>21</sup>, cardiac cells<sup>22</sup> and breast  
93 cancer cells<sup>23</sup>. Despite our expanded understanding of this transcription factor family,  
94 the specific function of each individual NFAT protein has been difficult to define fully due  
95 to the redundancy amongst the family members. This is due to highly homologous  
96 RHDs, which all bind to a core DNA sequence of (A/T)GGAAA<sup>11</sup>. On the other hand,  
97 their non-redundant roles are attributed to their interaction with other transcription  
98 factors via their dissimilar TADs<sup>24</sup>. Furthermore, NFATs can also alter the function of

99 other transcription factors by directly competing for binding sites, as has been reported  
100 with nuclear factor kappa B (NF- $\kappa$ B)<sup>25</sup>.

101 A particularly illustrative example of how critical calcineurin and NFATs are in immunity  
102 and clinical medicine is the fact that calcineurin inhibitors (e.g. cyclosporin A (CsA),  
103 tacrolimus [FK506], and pimecrolimus), which suppress T cells without significant  
104 myelotoxicity, have served as the standard of care over the past 40 years for preventing  
105 organ rejection and graft-versus-host disease in transplant recipients<sup>10, 26, 27, 28</sup>. Further,  
106 they have also been used successfully to treat a variety of immune-mediated disorders  
107 including atopic dermatitis, psoriasis, rheumatoid arthritis, and uveitis<sup>28, 29</sup>. However,  
108 despite the effectiveness of calcineurin inhibitors, serious adverse side effects have  
109 been reported, including nephrotoxicity, lymphomas, and increased susceptibility to  
110 infections<sup>30</sup>. Insight into NFAT biology in humans is thus critical to understand the  
111 mechanisms underlying the side-effects of these drugs.

112 One strategy to study human NFAT biology has been to use calcineurin inhibitors<sup>31</sup>.  
113 However, since they inhibit all members of the NFAT family, the role of individual  
114 members has been challenging to define. Similarly, although targeted genetic disruption  
115 of individual NFAT family members in mice has helped uncover their specific functions  
116 in murine immunity, this approach is not fully transferable to the human system. A  
117 powerful complementary approach is to identify and study rare individuals who carry  
118 damaging germline variants in genes encoding members of the NFAT family, allowing  
119 us to investigate their roles in an unmodified human system. Here, we report the  
120 identification and characterization of the first human with complete NFAT1 deficiency.

121

## 122 **METHODS**

### 123 **Study participants and consent**

124 All study participants and/or their parents/guardians provided written informed consent  
125 to participate. All individuals also provided consent to be published. Research study  
126 protocols (H18-02853 and H15-00092) were approved by The University of British  
127 Columbia Clinical Research Ethics Board.

128

### 129 **Identification of variant and confirmation by Sanger sequencing**

130 Trio whole exome sequencing (WES) was performed on genomic DNA from the patient  
131 and both parents on an Illumina platform at Ambry Genetics (Aliso Viejo, California,  
132 USA) after capture of targeted regions using xGen™ Exome Hybridization Panel (IDT,  
133 Coraville, Iowa, USA). More than 99% of targeted regions were covered by at least 10  
134 reads that averaged 150 bp in length. Reads were aligned to GRCh37/Hg19 and  
135 variants were called using BWA-MEM, GATK 3.5-0, SAMtools 0.1.19, and Picard 1.139,  
136 and then annotated and prioritized with VarSeq v.1.5 (Golden Helix, Bozeman,  
137 Montana, USA). WES data was analyzed using an updated version of our in-house,  
138 open-source, semi-automated bioinformatics pipeline that has been previously  
139 described<sup>32, 33</sup>. A predicted null *NFATC2* variant (c.2023\_2026delTACC,  
140 p.Tyr675Thrfs\*18) was selected for further analysis on the basis of: i) the clinical  
141 phenotype matching closely to that of *Nfatc2* knockout mice<sup>18, 34</sup>; ii) the variant resulting  
142 in a premature stop codon; and iii) the variant segregating with the disease in the  
143 extended family. The variant was confirmed by standard Sanger sequencing of genomic  
144 DNA from all individuals of the family. Briefly, genomic DNA was extracted from whole  
145 blood (QIAmp DNA Blood Mini Kit; Qiagen, Hilden, Germany) and buccal swabs  
146 (DNeasy Blood and Tissue Kit; Qiagen) according to manufacturer's recommendations.  
147 The variant region was PCR amplified using GoTaq Green Master Mix (Promega;  
148 Madison, Wisconsin, USA) and primers that flank the area: Forward: 5'-  
149 CAGGGACAGGAGTCATCCAC-3'; Reverse: 5'-AACACCCATTAGACAGTGGGC-3'

150 (Integrated DNA Technologies; Coralville, Iowa, USA). The PCR product was purified  
151 using a QIAquick PCR Purification Kit (Qiagen) and sequenced using the same primers.

152

### 153 **Cell isolation, culture, and immortalization of lymphoblastoid cell lines (LCLs)**

154 Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll-Paque  
155 (GE Healthcare, Chicago, Illinois, USA) density centrifugation from four discrete blood  
156 draws and time points from the patient over a span of two years, one time point from  
157 four heterozygous family members, and from eight unique age-matched healthy  
158 controls. PBMCs were cultured in complete RPMI-1640 (GE Healthcare) supplemented  
159 with 10% heat inactivated FBS (Gibco, Life Technologies; Rockville, Maryland, USA),  
160 2mM L-glutamine (HyClone, Thermo Fisher Scientific; Waltham, Massachusetts, United  
161 States), and 1mM sodium pyruvate (Gibco, Life Technologies; Carlsbad, California,  
162 USA) in the presence or absence of various stimuli described in the following sections.

163 Lymphoblastoid cell lines (LCLs) were derived by EBV transformation and cultured in  
164 complete RPMI-1640 as previously described by our group<sup>35, 36</sup>. Briefly, PBMCs from  
165 the patient (II-1), one heterozygous control (II-2), and one healthy control individual  
166 were cultured in complete RPMI-1640 media (GE Healthcare) supplemented with  
167 tacrolimus (AG Scientific, San Diego, California) for 1 h. Cells were then infected with  
168 supernatant from a viral replication-permissive marmoset cell line B95-8 (ATCC,  
169 Manassas, Virginia, USA) until sufficient B cell blasts were generated. LCLs were  
170 cultured in complete RPMI-1640 media without tacrolimus.

171 Chondrocytes were grown from an osteochondroma that was surgically removed from  
172 the patient's proximal tibia. The small cartilage component was excised from connective  
173 tissue and placed in separate wells in a 6-well plate and digested with 200 U/ml  
174 collagenase in complete Dulbecco's Modified Eagle Medium (DMEM; GE Healthcare)  
175 supplemented with 10% heat inactivated FBS (Gibco, Life Technologies, Rockville, Md),  
176 2mM L-glutamine (HyClone, Thermo Fisher Scientific), and 1mM sodium pyruvate  
177 (Gibco, Life Technologies) and 1x Antibiotic-Antimycotic (Gibco, Thermo Fisher) for 1

178 day at 37°C. Cells were filtered with a 40µM cell strainer and seeded in a monolayer  
179 and allowed to adhere.

180

### 181 **Stable expression of NFAT1 using a Lentivirus vector**

182 Stable expression of NFAT1 was established as previously described<sup>37, 38</sup>. Briefly, the  
183 NFATC2 (NM\_173091) gene was cloned out of a Myc-DDK-tagged NFATC2 plasmid  
184 (Cat#: RC213966, OriGene Technologies; Rockville, Maryland, USA) and cloned into a  
185 GFP-tagged Lenti vector (Cat#: PS100071, OriGene Technologies) using EcoRI-HF  
186 (Cat#: R3101) and NotI-HF (Cat#: R3189), both from New England BioLabs (Ipswich,  
187 Massachusetts, USA). GFP-tagged NFATC2 and GFP-expressing empty vector (EV)  
188 were packaged using 3rd generation packaging plasmids, and transfected into HEK  
189 293T cells. Culture media was collected, centrifuged, filtered, concentrated, and stored  
190 at -80°C before use.

191 To establish patient-derived chondrocytes that stably express WT NFAT1, chondrocytes  
192 were infected with EV or WT *NFATC2* lentiviral particles and 5µg/ml polybrene (Sigma-  
193 Aldrich, St Louis, Mo), cultured, and expanded in high glucose DMEM (HyClone)  
194 supplemented with 10% FBS and 2mM L-glutamine. Expanded cells were sorted on  
195 GFP expression using a BD FACS Aria (BD Biosciences) cell sorter. To establish  
196 patient T cells that express WT NFAT1, isolated PBMCs were stimulated with  
197 CD3/CD28 T cell activator (Cat#: 10971; Stemcell, Vancouver, Canada) for 3 days,  
198 infected with EV or WT *NFATC2* particles for 24 hours at 37°C, and stimulated with  
199 CD3/CD28 T cell activator for another 3 days before undergoing downstream flow  
200 cytometric analyses.

201

### 202 **Cytometric Bead Array (CBA)**

203 A cytokine bead array was used to measure cytokine production in chondrocytes as  
204 previously described<sup>39</sup>. Briefly, patient and WT-*NFATC2*-transduced chondrocytes were  
205 seeded in T25 flasks in complete DMEM media (GE Healthcare) without antibiotics and



206 allowed to reach confluency. Chondrocytes were washed and subsequently left  
207 untreated in media alone or stimulated with 50ng/mL phorbol 12-myristate 13-acetate  
208 (PMA) (Sigma) and 1 $\mu$ M ionomycin (Sigma) (P/I) or 20ng/mL IL-1 $\beta$  (Cat#: 14-8018-62;  
209 eBiosciences, San Diego, California, USA) at 37°C for 24h. Supernatants were  
210 collected and a human inflammatory cytokine CBA kit was used to measure the  
211 concentration of IL-6 (BD Biosciences, Cat#: 552932; Franklin Lakes, New Jersey,  
212 USA) according to manufacturer's recommendations<sup>40</sup>. Samples were acquired using a  
213 BD LSRII flow cytometer and analyzed using FlowJo (BD Biosciences).

214

## 215 **Immunoblotting**

216 Changes in NFAT1 expression and phosphorylation status was detected by stimulating  
217 LCLs with 10 $\mu$ M ionomycin for 10 min in complete RPMI or empty vector (EV)- or WT-  
218 *NFATC2*-transduced chondrocytes with P/I or 20ng/mL IL-1 $\beta$  for 15 min in complete  
219 DMEM at 37°C. Whole cell lysates were prepared by lysing untreated and stimulated  
220 LCLs or chondrocytes in a modified radio immunoprecipitation assay buffer with the Halt  
221 protease and phosphatase inhibitors cocktail (Thermo Fisher Scientific). Lysates were  
222 separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride  
223 membranes (Immobilon-FL; MilliporeSigma, Billerica, Massachusetts, USA).  
224 Membranes were blocked with 5% BSA in Tris-buffered saline with Tween-20,  
225 incubated with primary antibodies for 18h at 4°C, incubated with secondary antibodies  
226 for 1h at room temperature, and imaged using a LI-COR Odyssey infrared scanner (LI-  
227 COR Biosciences, Lincoln, Nebraska, USA). The primary antibodies used were the  
228 following: NFAT1 (Cat#: 4389) and  $\beta$ -actin (Cat#: 3700) both from Cell Signaling  
229 Technologies (Danvers, Massachusetts, USA). The secondary antibodies used were  
230 the following: goat anti-rabbit IgG DyLight 800 conjugated (611-145-002-0.5; Rockland  
231 Immunochemicals, Pottstown, Pennsylvania, USA) and goat anti-mouse IgG IRDye  
232 680RD (926-6870; LI-COR).

233

## 234 **Quantification of *NFATC2* transcript abundance by quantitative PCR (qPCR)**

235 qPCR was conducted as previously described<sup>35</sup>. Briefly, total RNA was extracted from  
236 unstimulated or 18h ionomycin-stimulated LCLs using a RNeasy Plus Mini Kit (Qiagen)  
237 and converted to cDNA using an iScript cDNA synthesis kit (BioRad Laboratories;  
238 Hercules, California, USA). Transcript abundance was measured using a Universal  
239 SYBR Green Super Mix (Bio-Rad) and a 7300 Real-Time PCR System (Applied  
240 Biosystems, Foster City, California, USA). The primers used for *NFATC2* were the  
241 following: Forward: 5'-GTCAGCCTCAGCACTTTACC-3'; Reverse: 5'-  
242 ATCAGAGTGGGGTCATATTCATC -3' (PrimeTime; Integrated DNA Technologies).  
243 Relative transcript abundance was quantified relative to *ACTB* using the  $2^{-\Delta\Delta CT}$   
244 method<sup>41</sup>.

245

## 246 RNA-Sequencing

247 To investigate the global transcriptome, EV- or WT-*NFATC2*-transduced chondrocytes  
248 were unstimulated, 4h P/I-stimulated, or 4h 20ng/mL IL-1 $\beta$ -stimulated. RNA was  
249 extracted in triplicate as previously described<sup>35</sup> using a RNeasy Mini Plus Kit (Qiagen)  
250 according to manufacturer's recommendations. RNA was prepared following the  
251 standard protocol for the NEBNext Ultra II Stranded mRNA (New England Biolabs) and  
252 sequenced on the Illumina NextSeq 500 with Paired End 42 bp x 42 bp reads. De-  
253 multiplexed read sequences were aligned to a reference sequence using Spliced  
254 Transcripts Alignment to a Reference (STAR) aligner. E1 Assembly and expression  
255 were estimated using Cufflinks E2 through bioinformatics apps on Illumina BaseSpace.

256 Expression data were normalized to reads between samples using the edgeR package  
257 in R (R Foundation, Vienna, Austria). Normalized counts were filtered to remove low  
258 counts using the filterByExpr function in edgeR<sup>42</sup>. Batch correction and differential  
259 expression was conducted using Limma<sup>43</sup>. Pathway analysis was done by first  
260 performing Gene Set Enrichment Analysis (GSEA) with 1000 permutations using the  
261 Molecular Signatures Database Hallmark module. Signal-to-noise ratio was used for  
262 gene ranking and the obtained NESs and P-values were further adjusted using the  
263 Benjamini-Hochberg method. Pathways with an adjusted P-value < 0.05 were  
264 considered significant. Leading edge genes from significant pathways between EV and

265 WT-*NFATC2*-transduced chondrocytes were identified. Expression levels of these  
266 genes were then determined in each group.

267 Sample level enrichment analyses (SLEA) scores were computed as previously  
268 described<sup>44</sup>. Briefly, z-scores were computed for gene sets of interest for each sample.  
269 The mean expression levels of significant genes were compared to the expression of  
270 1000 random gene sets of the same size. The difference between observed and  
271 expected mean expression was then calculated and represented on heatmaps  
272 generated using Morpheus (<https://software.broadinstitute.org/morpheus>). Raw data are  
273 deposited on Gene Expression Omnibus at the following accession number  
274 GSE193414.

275

## 276 **Single Cell RNA-Sequencing**

277 Targeted single cell RNA-Sequencing of 500 curated immune-related genes was  
278 conducted on PBMCs from the patient, three heterozygous controls, and two age-  
279 matched healthy controls using the BD Rhapsody Single Cell platform, the Rhapsody  
280 Cartridge Reagent Kit (BD, Cat#: 633731), the BD Rhapsody Cartridge Kit (BD, Cat#:  
281 633733), the Rhapsody cDNA Kit (BD, Cat#: 633733), the Rhapsody Targeted mRNA  
282 amplification Kit (Cat#: 633774), and the Human Single-Cell Multiplexing Kit (BD, Cat#:  
283 633781) according to manufacturer's recommendations. Briefly, thawed PBMCs were  
284 rested overnight and stimulated with P/I or left untreated for 4h. Cells from each donor  
285 were labelled with sample tags, washed with stain buffer and pooled together in cold  
286 sample buffer to obtain ~25,000 cells in 620ul for each of the unstimulated and  
287 stimulated samples. Two nanowell cartridges were primed and subsequently loaded  
288 with the pooled samples for 15min at room temperature on the Rhapsody Express  
289 instrument (BD, Cat#: 633702). Cell capture beads were prepared and loaded onto the  
290 cartridge. The cartridge was washed, cells were lysed, and beads were retrieved. The  
291 sample then underwent reverse transcription and exonuclease I treatment. cDNA was  
292 amplified using a custom immune panel (**Supp. Table 5**) via PCR. mRNA PCR products  
293 were separated from sample tag products with double-sided size selection using  
294 AMPure beads (Beckman Coulter, Cat#: A63880). Separated products were further

295 amplified by PCR and then purified using AMPure beads. Product quality was checked  
296 using Agilent DNA High Sensitivity Kit (Agilent Technologies, Cat#: 5067-4626) on the  
297 Agilent 2100 Bioanalyzer (Agilent Technologies, Cat#: G2940CA). PCR products were  
298 then PCR amplified using two index primers, one for unstimulated (5'-CGAGGCTG-3')  
299 and one for stimulated (5'-AAGAGGCA-3') samples. Indexed products were again  
300 purified using AMPure beads and sample quality was checked using the Agilent 2100  
301 Bioanalyzer. Libraries were diluted to 650pM and multiplexed for paired-end (2 x 115bp)  
302 sequencing on a NextSeq2000 Sequencing System (Illumina) at 200 cycles P3 for 1.1  
303 billion reads.

304 FASTQ files were processed using the BD Rhapsody Targeted Analysis Pipeline and  
305 Seven Bridges ([www.sevenbridges.com](http://www.sevenbridges.com)) according to manufacturer's  
306 recommendations. Briefly, R1 and R2 reads were filtered based on read length, quality,  
307 and highest single nucleotide frequency. R1 reads are annotated to identify cell labels,  
308 unique molecular identifiers (UMI), and filtered for >6 Poly(T) tail. Bowtie2 version 2.2.9  
309 was used to map the R2 reads to the reference sequences. All reads, R1 and R2, with  
310 the same cell label, UMI sequence, and gene were collapsed into a single molecule.  
311 Recursive substitution error correction (RSEC) and distribution-based error correction  
312 (DBEC) were used to adjust for PCR errors in UMI sequences (which can give rise to  
313 artifacts). Putative cells were determined by considering all reads associated with  
314 DBEC-adjusted molecules. The minimum second derivative along the cumulative reads  
315 curve is identified as the inflexion point, after which the cells are labelled as noise.  
316 Filtered putative reads that align to a sample tag sequence were used to identify sample  
317 labels for a cell. Finally, labelled DBEC-adjusted molecule counts were obtained in a  
318 CSV format for downstream analyses.

319 The R package Seurat<sup>45</sup> was utilized for all downstream analysis. No gene per cell  
320 cutoffs were imposed since we were using a targeted 500-gene panel. Scaling and  
321 clustering was performed on each pool of samples independently. Dimensionality  
322 reduction using PCA was based on all 500 genes and UMAP was based on the first 20  
323 PCs. Cell identities were first annotated with SingleR using fine labeling from the  
324 Novershtern hematopoietic dataset<sup>46, 47</sup>. The annotation was refined manually based on

325 the UMAP clustering patterns, grouping the SingleR labels into 8 main populations:  
326 Naïve B cells, Memory B cells, Naïve CD4<sup>+</sup>, Memory CD4<sup>+</sup>, Memory CD8<sup>+</sup>, Monocytes,  
327 NK cells, and undefined. For differential gene expression analyses, we utilized the  
328 Seurat implementation of negative binomial test, assuming an underlying negative  
329 binomial distribution in RNA-Seq data while leveraging the UMI counts to remove  
330 technical noise<sup>48, 49</sup>. Raw data are deposited on Gene Expression Omnibus at the  
331 following accession number GSE193410. All downstream analysis scripts used in  
332 analysis are available on GitHub ([https://github.com/maggie-fu/NFATC2\\_RNAseq/](https://github.com/maggie-fu/NFATC2_RNAseq/)).

333

### 334 **Lactate Dehydrogenase (LDH) Assay**

335 Chondrocyte resistance to cell death was quantified using a lactate dehydrogenase  
336 assay (LDH) according to manufacturer's instructions (Promega, Cat#: G1780). Briefly,  
337 EV- or WT-*NFATC2*-transduced chondrocytes were seeded in 96-well plates at a  
338 concentration of 5000 cells/well. Cells were rested until they reached confluency and  
339 subsequently stimulated with P/I over a time course, including 0, 2, 4, 6, 8, 10, and 12  
340 days at 37°C. 50 µl of cell supernatants were collected, added to 50µl of CytoTox96  
341 reagent, and incubated in the dark for 30 min at room temperature. The reaction was  
342 subsequently stopped with 50µl of stop solution. Maximum LDH release was measured  
343 at each time point by lysing cells. Absorbance was measured on the Infinite M200 plate  
344 reader (Tecan; Männedorf, Switzerland) at 492nm. Cell death was defined as a  
345 percentage of maximum LDH release.

346

### 347 **B cell expansion and differentiation**

348 Naïve B cells were isolated from PBMCs of the patient, one heterozygous family  
349 member and 6 healthy controls using the EasySep Human Naïve B Cell Isolation Kit  
350 (Cat#: 17254; Stemcell) according to manufacturer's recommendations. Cells were  
351 stained with the 'Plasmablast Differentiation' panel (**Supp. Table 6**) described in the  
352 'Flow Cytometry' section before and after stimulation with ImmunoCult-ACF Human B

353 Cell Expansion Supplement (Cat#: 10974; Stemcell) for 6 days in order to determine the  
354 proportion of different subsets by flow cytometry.

355

### 356 **Clinical-Grade Flow Cytometry**

357 Patient clinical immunophenotyping was also carried out at an accredited clinical flow  
358 cytometry laboratory. Whole blood was collected and stained using DURAClone tubes  
359 (Beckman Coulter; Brea, California, USA) according to the manufacturer's  
360 recommendation. Briefly, fresh blood was incubated with dried reagent tubes and  
361 incubated in the dark at room temperature for 15 min. Cells were washed in 3mL of PBS  
362 2 times, before being fixed in 500uL of PBS containing 0.1% formaldehyde and  
363 subsequently acquired. Panels focused on the analysis of T cell subsets (DURAClone  
364 IM T Cell Subsets, Beckman Coulter; Cat#: B53328) and B cell subset (DURAClone IM  
365 B Cell, Beckman Coulter; Cat#: B53318). All flow data were acquired on a Navios flow  
366 cytometer and then analyzed using Kaluza software (Beckman Coulter).

367

### 368 **Research-Grade Flow Cytometry**

369 To carry out immunophenotyping and intracellular cytokine detection, PBMCs from the  
370 patient, heterozygous family members, and age-matched controls were stimulated with  
371 P/I for 4h at 37°C in the presence of GolgiStop (Cat# 554724, BD Biosciences).  
372 Following stimulation, cells were stained with a cocktail of antibodies against surface  
373 markers for 20 min on ice then fixed with the Foxp3 Fixation/Permeabilization working  
374 solution (Cat#: 00-5123-43; Invitrogen, Thermo Fischer Scientific) from the eBioscience  
375 Foxp3 Transcription Factor Staining Buffer Set (Cat# 00-5523-00, Invitrogen, Thermo  
376 Fisher Scientific) for 20 min. Fixed cells were then stained with antibodies directed  
377 against intracellular cytokines or transcription factors for 45 min in 1x Permeabilization  
378 Buffer (Cat#: 00-8333-56; Invitrogen, Thermo Fischer Scientific). Samples were then  
379 washed and analyzed on the BD FACSymphony flow cytometer (BD Biosciences). Data  
380 were analyzed using FlowJo software (BD Biosciences). Antibody panels used for  
381 staining are listed in **Supp. Table 6**.

382

383 **Histology**

384 Formalin-fixed, paraffin-embedded lymph node tissue was sectioned at 4 $\mu$ M and  
385 subjected to routine hematoxylin and eosin (H&E) staining or immunohistochemistry  
386 (IHC). The following IHC antibodies were used: CD21 (IF8, Dako), CD20 (L26,  
387 Ventana), BCL6 (P6-B6P, Dako), CD30 (Ber-H2, Ventana), and BCL2 (124, Dako).  
388 CD21, BCL6, and BCL2 IHC were performed on the Dako Autostainer. CD20 and CD30  
389 IHC were performed on the Dako Omnis Automated Slide Stainer.

390

391

## 392 RESULTS

### 393 Clinical features of complete human NFAT1 deficiency

394 The patient (designated II-1 on the family pedigree) is born to consanguineous parents.  
395 After a healthy birth, the patient started developing difficulty bending his knees with no  
396 associated swelling, pain, erythema, or morning stiffness in early childhood (ages 0-5  
397 years). Insidiously, many joints developed a similar painless decreased range of motion  
398 causing difficulty with ambulation. Medical care was disjointed until the patient was in  
399 his teenage years (ages 15-20 years). Assessment then demonstrated a  
400 neurodevelopmentally normal young man with marked bilateral fixed flexion  
401 contractures of knees, hips, and ankles. Multiple upper limb joints also demonstrated  
402 reduced range of motion, including wrists, hands, and shoulders (**Fig. 1A, Table 1**).  
403 Muscle strength and deep tendon reflexes were all intact. The joint changes significantly  
404 impacted his gait, causing him to walk with an increased anterior pelvic tilt, and leading  
405 to decreased dynamic hip range of motion with particularly diminished extension  
406 through mid to late stance. He also had diminished dynamic knee range of motion with  
407 knee flexion throughout stance and swing and mild equinus bilaterally at his ankles  
408 (**Supp. Table 1**). He had absent distal digital creases and prominent fetal fat pads on all  
409 fingers. Echocardiography showed a mildly hypertrophied left ventricle with multiple  
410 cords and an appearance of coarse trabeculae on the septal and free wall surfaces.  
411 Dual-energy X-ray absorptiometry (DEXA) scanning revealed low total body bone  
412 mineral density ( $0.888 \text{ g/cm}^2$ , z-score for chronologic age being  $-1.9$  [ $-0.4$  after adjusting  
413 for height]). X-rays showed flattening of multiple lower thoracic and lumbar vertebral  
414 bodies suggesting mild vertebral compression fractures. Two  
415 osteochondromas/exostoses were also identified; one on the medial aspect of the right  
416 proximal tibial metaphysis (2cm) and a second on the anterior aspect of the right  
417 proximal fibula (3cm) (**Fig. 1A, 1B**). In summary, the main musculoskeletal findings are  
418 contractures of the large and small joints of the upper and lower limbs,  
419 osteochondromas, and osteopenia (**Table 1**).

420 In his late teens (ages 15-20 years), the patient presented with abdominal pain, fever,  
421 night sweats and weight loss (i.e. B symptoms) and was ultimately diagnosed B-cell



422 lymphoma, unclassifiable, with features intermediate between diffuse large B-cell  
423 lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL). Lymphoid tissue biopsy  
424 showed effacement of typical node architecture and the absence of clear germinal  
425 centers and follicular structure. There was a prominent population of larger atypical  
426 lymphocytes (CD79a<sup>+</sup>CD30<sup>+</sup>CD20<sup>+</sup>CD15<sup>-</sup>BCL6<sup>+</sup>) in the background of mature CD4<sup>+</sup> and  
427 CD8<sup>+</sup> T cells (**Fig. 1C**). He was staged as Ann Arbor stage 4B with widespread disease,  
428 including abdominal, inguinal, hepatic, splenic, paratracheal, and subcarinal  
429 lymphadenopathy. The patient was treated with 6 cycles of a modified dose-adjusted  
430 EPOCH-R regimen without vincristine and went into full remission.

431

### 432 **Whole-exome sequencing (WES) reveals a novel damaging homozygous variant** 433 **in *NFATC2***

434 Given the unique phenotype of the patient, consanguinity, and significant family history,  
435 we performed whole exome sequencing (WES) to identify a potential genetic etiology.  
436 The patient was found to carry a previously unreported homozygous 4-base pair  
437 deletion in exon 8 of the gene *nuclear factor of activated T cells 2 (NFATC2)* encoding  
438 the NFAT1 transcription factor. This variant causes a frameshift leading to a premature  
439 stop codon (NM\_173091:c.2023\_2026delTACC; NP\_775114:p.Tyr675Thrfs\*18).  
440 Sanger sequencing of the variant region in whole blood confirmed that it segregated  
441 with disease within the patient family (**Fig. 1D, 1E**). The variant localizes to the DNA  
442 binding domain of the NFAT1 protein and affects an evolutionarily conserved region  
443 (**Fig. 1F**).

444 This variant led to significantly reduced *NFATC2* transcript abundance in patient-derived  
445 lymphoblastoid cell lines (LCLs) when compared to heterozygous control- and unrelated  
446 control-derived LCLs (**Fig. 1G**). To investigate the impact on NFAT1 protein function,  
447 we measured NFAT1 expression in LCLs pre- and post-stimulation with the NFAT1  
448 activator, ionomycin (**Fig. 1H**), and in the absence or presence of the calcineurin  
449 inhibitor tacrolimus (FK506). We confirmed that NFAT1 expression was undetectable in  
450 patient LCLs, but reduced in heterozygous control LCLs (**Fig. 1I**). Furthermore, NFAT1  
451 was strongly dephosphorylated in both wild-type and heterozygous control LCLs

452 following ionomycin stimulation and this effect was effectively inhibited by FK506  
453 treatment (**Fig. 1G, 1I**).

454

### 455 **NFAT1-deficient patient chondrocytes are more enriched in cell proliferation and** 456 **inflammatory genes with elevated IL-6 production and resistance to cell death**

457 Informed by the patient's joint contractures and osteochondromas, we assessed the  
458 impact of NFAT1 deficiency on chondrocytes isolated from the excised tibial  
459 osteochondroma. Patient chondrocytes had undetectable NFAT1 expression (**Fig. 2A**).  
460 To study the impact of NFAT1 deficiency on chondrocytes, we engineered a *WT*  
461 *NFATC2* lentivirus construct and transduced patient chondrocytes to rescue NFAT1  
462 expression. This restored function to the pathway as demonstrated by NFAT1  
463 dephosphorylation that was sensitive to FK506 inhibition (**Fig. 2A**). Further, treatment  
464 with IL-1 $\beta$ , a key cytokine involved in cartilage damage in arthritis<sup>50</sup>, did not change  
465 NFAT1 phosphorylation status.

466 To define the impact of NFAT1 deficiency on the global transcriptome of chondrocytes,  
467 we conducted bulk RNA-Seq on empty vector (EV) or *WT NFATC2*-transduced patient  
468 chondrocytes untreated or stimulated with P/I or IL-1 $\beta$ . We identified 187 significantly  
469 upregulated and 146 significantly downregulated genes between P/I-stimulated *WT*  
470 *NFATC2*- and EV-transduced chondrocytes, which may represent NFAT1 suppressed  
471 and enhanced genes, respectively (**Fig. 2B, 2C**). Gene set enrichment analysis (GSEA)  
472 identified significant enrichment in pathways involved with cellular growth and  
473 inflammation (**Fig. 2D**). Notable was the enrichment of cell proliferation pathways both  
474 at baseline and in response to P/I stimulation in NFAT1-deficient EV-transduced  
475 chondrocytes, including G2/M Checkpoint (unstimulated: NES=1.790, FDR<0.001; P/I  
476 stimulated: NES=1.544, FDR=0.047) and E2F targets (unstimulated: NES=1.704,  
477 FDR=0.004; stimulated: NES=1.667, FDR=0.013) (**Fig. 2D**). To assess the functional  
478 consequences of these transcriptomic findings, we stimulated EV- and *WT NFATC2*-  
479 transduced chondrocytes over a time course up to 12 days with P/I and monitored cell  
480 survival. Here, we discovered that EV-transduced NFAT1-deficient chondrocytes were

481 significantly more resistant to cell death than WT *NFATC2*-transduced chondrocytes  
482 (**Fig. 2E**).

483 The IL-6-JAK-STAT3 signaling pathway was also significantly enriched in unstimulated  
484 EV-transduced NFAT1-deficient chondrocytes (NES=1.543, FDR=0.035) (**Fig. 2D**).  
485 Confirming this at the protein level, both unstimulated and P/I-stimulated EV-transduced  
486 NFAT1-deficient chondrocytes produced significantly more IL-6 than 'rescued' WT-  
487 transduced chondrocytes (**Fig. 2F**). Taken together, these findings suggest that NFAT1  
488 regulates chondrocyte growth, death, and proinflammatory transcriptional programs,  
489 collectively leading to aberrant connective tissue homeostasis.

490

### 491 **NFAT1 deficient B cells are largely naïve *ex vivo* and express proliferation** 492 **markers**

493 Given that NFAT1 is expressed in most lymphocytes<sup>16</sup>, we conducted targeted single  
494 cell RNA-Sequencing (scRNA-Seq) on patient PBMCs alongside 5 healthy controls (2  
495 age-matched sex-matched healthy controls and 3 heterozygous family members)  
496 stimulated with P/I to identify cell type-specific defects. Unsupervised clustering analysis  
497 revealed markedly reduced memory B cells and elevated memory CD4<sup>+</sup> T cells in the  
498 patient PBMCs (**Fig. 3A**).

499 Since patient B cells were largely naïve, we focused our differential gene expression  
500 (DE) analysis on patient and control naïve B cells (**Fig. 3B**). We discovered significantly  
501 increased transcript abundance of pro-survival, proliferation, and anti-apoptotic genes  
502 frequently associated with lymphoma in patient cells compared to controls. This  
503 includes *MYC*<sup>51</sup>, *HIF1A*<sup>52</sup>, *JAK1*, *STAT3*<sup>53</sup>, *TNFAIP8*<sup>54</sup>, and *PIK3AP1*<sup>55</sup> (**Fig. 3C**).  
504 Consistent with the documented NFAT1 deficiency, classical NFAT1 targets such as  
505 *TNF* and *LTA*<sup>56, 57</sup> were significantly decreased in patient naïve B cells.

506 To study this B cell phenotype further, we carried out multi-parameter flow cytometric  
507 analyses on PBMCs from the patient, 4 heterozygous healthy family member, and 8  
508 healthy controls (see **Supp. Fig. 1A** for gating strategy). Direct detection of NFAT1  
509 protein confirmed the lack of NFAT1 in patient B cells as compared to controls (**Fig.**

510 **3D**). Validating our scRNA-Seq data, and consistent with clinical-grade flow cytometry  
511 (**Supp. Table 2**), patient B cells showed signs of a developmental arrest, with  
512 significantly elevated transitional B cells (**Fig. 3E, 3F**) and naïve B cells (**Fig. 3G, 3I**)  
513 with a concurrent reduction in class-switched memory B cells (**Fig. 3G, 3H**).  
514 Interestingly, despite the reduced frequency of memory B cells in the patient,  
515 plasmablast numbers were comparable to controls (**Fig. 3J**) (**Supp. Fig. 1A**), perhaps  
516 explaining the patient's normal serum immunoglobulin levels.

517 Expanding our naïve B cell analyses further, we observed markedly elevated IgD  
518 expression (**Fig. 3K**) (**Supp. Fig. 1B**) and generally comparable to control IgM  
519 expression (**Fig. 3K**) (**Supp. Fig. 1C**) in patient naïve B cells. These IgD<sup>hi</sup> naïve B cells  
520 were characterized by elevated expression of the cell proliferation marker Ki67 (**Fig. 3L,**  
521 **3M**), but significantly reduced TNF- $\alpha$  expression (**Fig. 3N, 3O**) which was consistent  
522 with the scRNA-Seq data.

523 Given the striking B cell differentiation defect in the patient, we next asked whether this  
524 was intrinsic or extrinsic to B cells. We isolated naïve B cells from the patient and  
525 controls and quantified the frequency of class-switched memory B cells and  
526 plasmablasts before and after treatment with an *in vitro* B cell activation and expansion  
527 cocktail. We demonstrated intact differentiation of both memory B cells (**Fig. 3P**) (**Supp.**  
528 **Fig. 1D**) and plasmablasts (**Fig. 3P, 3Q**), suggesting that the differentiation defect is  
529 likely to be extrinsic to B cells.

530

### 531 **NFAT1 deficient CD8<sup>+</sup> T cells show impaired polyfunctionality**

532 Since both NFAT1 deficiency and calcineurin inhibitor treatment are known to suppress  
533 CD8<sup>+</sup> T cell effector function<sup>58, 59</sup> and suppressed CD8<sup>+</sup> T cells can create conditions  
534 that favour lymphomagenesis<sup>60</sup>, we next analyzed CD8<sup>+</sup> T cell differentiation and  
535 function by scRNA-Seq and flow cytometry. DE analysis of patient memory CD8<sup>+</sup> T cells  
536 revealed a mixed effector function defect, including decreased transcript abundance of  
537 *TNF*, *IFNG*, and *FASLG*, but increased *GZMH*, *GNLY*, and *PFN1* (**Fig. 4A, 4B**). Flow  
538 cytometric analysis of CD8<sup>+</sup> T cell subsets revealed no differences in patient naïve and

539 memory populations when compared to controls (**Fig. 4C, 4D**). However, whereas  
540 control CD8 populations expressed easily detectable levels of NFAT1 protein, patient  
541 CD8 populations were NFAT1-deficient (**Fig. 4E**). In line with the abnormal effector  
542 marker profile in scRNA-Seq, patient CD8<sup>+</sup> memory T cells showed significantly  
543 impaired expression of TNF- $\alpha$  and IFN- $\gamma$  expression in response to stimulation (**Fig. 4F-**  
544 **4H**). In contrast, IL-2 expression was intact in both patient naïve and memory CD8<sup>+</sup> T  
545 cells (**Supp. Fig. 2A-D**). Patient CD8<sup>+</sup> memory T cells also exhibited abnormal  
546 expression of activation markers, including comparable to control expression of CD40L  
547 (**Supp. Fig. 2E-F**) and PD-1 (**Fig. 4I**) (**Supp. Fig. 2H**), but elevated CD69 (**Fig. 4I**)  
548 (**Supp. Fig. 2G**). These findings indicate a pleiotropic function for NFAT1 in human  
549 CD8<sup>+</sup> T cells.

550

### 551 **NFAT1 deficiency causes an accumulation of non-functional memory CD4<sup>+</sup> T cells**

552 The role of NFAT1 in CD4 cell functionality and differentiation is well characterized in  
553 mouse studies<sup>14</sup>. We sought to see if this held true in human complete NFAT1  
554 deficiency. scRNA-Seq revealed a marked increase in the memory CD4<sup>+</sup> T cell  
555 compartment (**Fig. 3A**). We conducted DE analysis on these cells and found  
556 significantly impaired expression of many makers for T helper function (i.e. *TNF* and  
557 *CD40LG*) and cell proliferation (i.e. *MYC*) (**Fig. 5A, 5B**). In addition, we observed  
558 increased expression of other activation/exhaustion-related genes such as *TIGIT*,  
559 *S100A10* and *TNFRSF4* (**Fig. 5A, 5B**). Interestingly, many regulatory components of  
560 the NF- $\kappa$ B pathway (*NFKBIZ*, *NFKBIA*, *REL*) and AP-1 pathway (*FOS* and *JUN*)  
561 showed impaired expression in NFAT1 deficient cells (**Fig. 5A, 5B**), highlighting the  
562 broad defects associated with human NFAT1 deficiency.

563 We next examined the impact of NFAT1 deficiency on CD4<sup>+</sup> T cell differentiation by flow  
564 cytometry. Confirming our scRNA-Seq data, the patient possessed decreased naïve  
565 CD4<sup>+</sup> T cells with a concurrent increase in CD4<sup>+</sup> central memory T cells (**Fig. 5C, 5D**,  
566 **Supp. Table 2**) and both these subsets had undetectable levels of NFAT1 protein, in  
567 contrast to controls (**Fig. 5E**). Within the memory CD4<sup>+</sup> T cell compartment, the patient  
568 had significantly decreased T<sub>H1</sub>, T<sub>H2</sub>, T<sub>H17</sub> and T<sub>FH</sub> cells as measured by cytokine (i.e.

569 IFN- $\gamma$ , IL-4, IL-17A and IL-21) production (**Fig. 5F–5K**). Furthermore, classical NFAT1  
570 targets IL-2 and TNF- $\alpha$ <sup>7</sup>, were significantly reduced in patient memory CD4<sup>+</sup> T cells  
571 (**Fig. 5L, 5M**). In contrast, naïve CD4<sup>+</sup> T cells did not exhibit any significant differences  
572 in the expression of these same cytokines (**Supp. Fig. 3A-3I**).

573

#### 574 **Human NFAT1 deficiency does not cause any overt defects in Tregs**

575 Since NFAT1 was shown to be critical for controlling Treg suppressive function in  
576 mouse models<sup>61</sup>, we studied whether Treg development and/or function was affected in  
577 NFAT1 deficiency. Surprisingly, we found normal frequencies of Tregs and their naïve  
578 and activated subsets (**Supp. Fig. 5A-5C**). From a functional standpoint, activated  
579 patient Tregs showed significantly reduced TNF- $\alpha$  (**Supp. Fig. 5D-5E**), but normal IFN- $\gamma$   
580 (**Supp. Fig. 5D-5E**) and IL-2 (**Supp. Fig. 5G-5H**) expression. Similarly, Treg markers of  
581 stability and activation were largely normal, including FOXP3, Helios, CD25, CD69,  
582 CTLA4, and ICOS (**Supp. Fig. 5I-5N**), except for PD-1, which was significantly elevated  
583 (**Supp. Fig. 5O**).

584

#### 585 **NFAT1 deficiency impairs T<sub>FH</sub> function**

586 Given the impaired production of a variety of T cell cytokines (**Fig. 5F-5N**) by CD4<sup>+</sup>  
587 memory T cells, we asked whether the expression of activation markers and critical T  
588 cell coreceptors by this T cell population is affected by NFAT1 deficiency. Here we  
589 found significantly increased CD69, PD-1, and ICOS, but decreased CD25 and CD40L  
590 after P/I treatment (**Fig. 6A**) (**Supp. Fig. 3P-3T**). A similar profile was observed in naïve  
591 CD4<sup>+</sup> T cells (**Supp. Fig. 3K-5O**).

592 Reduced CD4<sup>+</sup> memory T cell activation marker expression and cytokine secretion  
593 paired with an extrinsic B cell differentiation defect prompted us to assess frequency  
594 and function of circulating T<sub>FH</sub> cells in the patient (**Supp. Fig. 4A**). Confirming cytokine  
595 staining (**Fig. 5F-5K**), T<sub>FH</sub> numbers were comparable to controls (**Fig. 6B, 6C**). Despite  
596 this, the expression of CD40L and IL-21, both important for B cell activation and

597 differentiation<sup>62</sup>, was markedly impaired (**Fig. 6D-6F**). Importantly, these defects were  
598 reversed when we transduced patient CD4<sup>+</sup> T cells with WT *NFATC2*, which restored  
599 CD40L and TNF- $\alpha$  expression to a level that was comparable to healthy controls (**Fig.**  
600 **6G-6I**).

601

602

## 603 DISCUSSION

604 Here we present a comprehensive clinical, immunological, biochemical, and  
605 transcriptional workup of the first reported case of human complete NFAT1 deficiency in  
606 a young man with a clinical triad of: progressive joint contractures, osteochondromas,  
607 and B cell malignancy. Based on our study, patients should be worked up for possible  
608 NFAT1 deficiency if they present with this triad of features. Although the full phenotype  
609 of human NFAT1 deficiency will only be appreciated when more affected individuals are  
610 identified, other clinical flags include: i) impaired B cell development (increased naïve,  
611 decreased memory); ii) normal CD8<sup>+</sup> T cell development but impaired TNF- $\alpha$  and IFN- $\gamma$   
612 production and elevated CD69 expression; and iii) increased CD4<sup>+</sup> memory proportions  
613 with reduced T<sub>H</sub> subsets and cytokine secretion, and increased CD69, PD-1, ICOS  
614 expression. Notably, haploinsufficiency (at least with this particular null variant) was not  
615 observed as all heterozygous family members were healthy and unaffected.

616 Studying *Nfatc2*<sup>-/-</sup> mice has been extremely informative in defining the physiological  
617 functions of NFAT1. This includes regulation of chondrogenesis<sup>18</sup> and bone  
618 development<sup>19, 63</sup>, maintenance of steady state hematopoiesis<sup>63</sup>, suppression and  
619 regulation of T cells<sup>64, 65</sup>, and B cell lymphomagenesis<sup>34</sup>. Reassuringly, human NFAT1  
620 deficiency recapitulates a variety of the features seen in the knockout mice (**Table 2**).  
621 The joint contractures and progressive difficulty in ambulation observed in our NFAT1-  
622 deficient patient were accurately predicted by *Nfatc2*<sup>-/-</sup> mice, as was the with excess  
623 differentiation, proliferation, and endochondral ossification affecting cartilage cells<sup>18</sup>. The  
624 pro-growth, pro-survival, and proinflammatory phenotype of patient chondrocytes (**Fig.**  
625 **2**) suggests that human NFAT1 serves as a repressor of cartilage cell growth and  
626 differentiation. Future work will focus on studying how osteopenia arises in the context  
627 of human NFAT1 deficiency and the contributions of different mesenchymal cells to the  
628 patient's musculoskeletal phenotype. Interestingly, bone fractures and osteopenia have  
629 also been observed in *Nfatc2*<sup>-/-</sup> or tacrolimus-treated mice<sup>19</sup>, and organ transplant  
630 recipients on immunosuppressive regimens that include glucocorticoids and  
631 tacrolimus<sup>66</sup>, further strengthening the link to NFAT1 function. In light of these  
632 observations, it is important to consider other findings in *Nfatc2*<sup>-/-</sup> mice, notably the



633 development of chondrosarcomas<sup>18</sup> and susceptibility to osteoarthritis<sup>20</sup>, as additional  
634 patients with NFAT1 deficiency are identified.

635 One of the most significant phenotypes in our patient was the development of a rare  
636 mature B cell lymphoma characterized by large CD20<sup>+</sup>CD30<sup>+</sup>CD15<sup>-</sup>BCL6<sup>+</sup> cells (**Fig.**  
637 **1C**). Intriguingly, an increased incidence of anaplastic and/or plasmablastic  
638 plasmacytomas –also rare– was also observed with aging *Nfatc2*<sup>-/-</sup> mice<sup>34</sup>. Abrogation  
639 of NFAT1 function in B cells may confer an intrinsic pro-survival transcriptional program.  
640 NFAT1 is critical for repressing cell cycle progression through cyclin E (*CCNE2*)<sup>67</sup> and  
641 our findings extend this understanding to suggest that JNK signaling (via *DUSP4*<sup>68</sup>) and  
642 AKT signaling (via *PIK3AP1*<sup>55</sup>) (**Fig. 3B, 3C**), might contribute to dysregulated B cell  
643 proliferation in the context of NFAT1 deficiency. In parallel, the CD4<sup>+</sup> T cells of the  
644 NFAT1-deficient patient expressed high levels of the inhibitory checkpoint marker, PD-1  
645 (**Fig. 6A**), which has frequently been associated with B cell lymphomas<sup>69, 70</sup>. This could  
646 inhibit effective anti-tumour effector functions in the patient. This is likely further  
647 exacerbated by the markedly reduced production of effector cytokines (TNF- $\alpha$ , IFN- $\gamma$ ) in  
648 patient's CD4<sup>+</sup> and CD8<sup>+</sup> T cells (**Fig. 4-5**). Together these data indicate that ongoing  
649 clinical tumor surveillance, and a heightened awareness of tumor risk, will be an  
650 important aspect of the long-term care of patients with NFAT1 deficiency.

651 Studying complete human germline NFAT1 deficiency can provide new insights into the  
652 use of calcineurin inhibitors and improves our understanding of the consequences of  
653 long-term NFAT1 inhibition by calcineurin inhibitors (**Table 2**). Patients undergoing solid  
654 organ or allogeneic hematopoietic stem cell transplantation are frequently treated with  
655 an immunosuppressive regimen including a calcineurin inhibitor for extended periods of  
656 time. This can lead to a rare complication called post-transplant lymphoproliferative  
657 disorder (PTLD). Most PTLD's are a B cell proliferative disorder believed to be due to  
658 impaired CD8<sup>+</sup> T cell function and EBV infection<sup>71,72</sup>. Our findings complement this  
659 understanding since NFAT1-deficient CD8<sup>+</sup> T cells express significantly reduced  
660 cytotoxic mediators such as *FASLG* and *IFNG* (**Fig. 4B, 4H**). Consistent with NFAT1-  
661 dependent regulation of the transcription factor *Egr3* being critical for FasL induction<sup>73</sup>,  
662 we found that both *EGR3* and *FASLG* were downregulated in CD4<sup>+</sup> and CD8<sup>+</sup> patient

663 memory T cells (**Fig. 4-5**). Future work should focus on the role of NFAT1 in intrinsic B  
664 cell proliferation and CD4<sup>+</sup> T cell exhaustion and the role of these factors in the  
665 pathophysiology of PTLD.

666 Mechanistically, human NFAT1 deficiency has revealed the remarkable pleiotropic and  
667 cell-type specific functions of NFAT1. Our study supports previous work that ascribed  
668 both oncogenic and tumor suppressor roles to NFAT1, depending on the cell type<sup>24</sup>.  
669 Informed by this patient, NFAT1 serves as a tumor suppressor in chondrocytes and B  
670 cells. This work also clarifies the role of human NFAT1 in B cell class-switching.  
671 Specifically, the B cell differentiation block is likely attributable to impaired T cell help.  
672 Previous studies demonstrated that both NFAT1 and NFAT2 are important for T<sub>FH</sub>  
673 differentiation<sup>15</sup>. However, this NFAT1-deficient patient demonstrates that human  
674 NFAT1 is likely dispensable for T<sub>FH</sub> differentiation but is critical for T<sub>FH</sub> activation and  
675 function (**Fig. 6B-I**). Similarly, NFAT1 is essential for T<sub>H</sub> cell differentiation and cytokine  
676 production (**Fig. 5F-5N**). One possible explanation for impaired CD4<sup>+</sup> memory function  
677 could be that they are exhausted. This is supported by high PD-1 (**Fig. 6A**), and *TIGIT*  
678 (**Fig. 5A-5B**) expression<sup>74</sup>.

679 Accumulation of memory T cells<sup>34, 75</sup>, along with hyperresponsiveness has been  
680 documented in T cells of *Nfatc2*<sup>-/-</sup> mice<sup>64, 65, 75, 76</sup>. We observed suppressed cytokine  
681 signaling in the patient memory CD4<sup>+</sup> and CD8<sup>+</sup> cells. However, patient naïve CD4<sup>+</sup> T  
682 cells do display signatures of activation, with higher PD-1 and CD69 (**Supp. Fig. 2J –**  
683 **2T**), as well as higher expression of T cell activation markers *CXCR3*<sup>77</sup>, *ITGA4* (an α  
684 subunit of integrin receptors), and *IL2RB* (CD122) (**Supp. Table 3**), a cytokine receptor  
685 recently found to be involved in homeostatic proliferation of naïve CD4<sup>+</sup> T cells<sup>78</sup>. Higher  
686 activation status in naïve T cells might explain the age-associated accumulation of  
687 memory T cells observed in knock-out mice<sup>34</sup> and the NFAT1-deficient patient.

688 Given the significant T and B cell dysregulation identified in this NFAT1-deficient patient  
689 and the absence of classical features for immunodeficiency (recurrent/severe/unusual  
690 infections), we propose to classify human NFAT1 deficiency as a primary immune  
691 regulatory disorder<sup>79</sup>. Studying this first reported patient has given us unique insight into  
692 the role of NFAT1 in the human musculoskeletal and immune systems. Our findings

693 corroborate decades of *Nfatc2*<sup>-/-</sup> murine studies, while also providing a mechanistic  
694 understanding of human NFAT1 deficiency in different cell types. Beyond individual  
695 patients, this study also informs the clinical implementation of calcineurin inhibitors and  
696 highlights potential adverse consequences of long-term use.

697

698 **Table 1: Major Clinical Features.** Patient clinical features organized by  
 699 musculoskeletal or immunological/hematological abnormalities.

700

701

<b>Musculoskeletal</b>	<b>Immunological/Hematological</b>
Contractures of upper limb joints, hips, knees, ankles	B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL
Mobility issues: stiff gait, decreased stride length, toe walking	Widespread lymphadenopathy: abdominal, inguinal, hepatic, splenic, paratracheal, subcarinal, bone. No bone marrow involvement.
Decreased arm swing and knee range of motion. Anterior pelvic tilt with adduction of thighs	Lymph node tissue demonstrates malignant, large, mono- or binucleated cells within a benign background inflammatory cell infiltrate composed of small lymphocytes, eosinophils, histiocytes, and neutrophils
Ill-defined sclerotic bands present in the metaphyses of both the femoral tibia and fibula	Lymph node: effaced/abnormal architecture, large atypical CD79a <sup>+</sup> CD30 <sup>+</sup> CD20 <sup>+</sup> CD15 <sup>-</sup> PAX5 <sup>+</sup> B cells, positive BCL6 rearrangement, negative BCL2 rearrangement
Presence of multiple small pedunculated osteochondromas Developed severe spinal cord stenosis at level C3 C4, requiring posterior cervical decompression and fusion	
Bone Density Scan (DEXA): <u>Lumbar spine L1-4:</u> 0.739 (g/cm <sup>2</sup> ); Z-Score for chronologic age: -1.4; Z-score corrected for height: +0.2 <u>Total left hip:</u> 0.865 (g/cm <sup>2</sup> ); Z-Score for chronological age 1.0; Z-score corrected for height: +0.2 <u>Total body:</u> 0.888 (g/cm <sup>2</sup> ); Z-Score for chronologic age: -1.9; Z-score corrected for height: -0.4	
No evidence of muscle necrosis or regeneration, no increased endomysia fibrous tissue, no inflammation, no atypical cells	

702

703

704

705

706 **Table 2: Comparison of human NFAT1 deficiency, *Nfatc2*<sup>-/-</sup> mice, and patients on**  
 707 **calcineurin inhibitors.**

	<b>NFAT1 deficient patient</b>	<b><i>Nfatc2</i><sup>-/-</sup> KO mice</b>	<b>Use of calcineurin inhibitors</b>
<b>Skeletal abnormalities and cartilage/chondrocyte defects</b>	Joint contractures, difficulty in ambulation. decreased range of motion in joints.	Joint contractures, difficulty in ambulation. decreased range of motion in joints <sup>18</sup> .	
	Increased cell cycling, resistance to apoptosis in osteochondroma chondrocytes	Invasive cartilage cells <i>in vivo</i> and contact-induced growth inhibition <i>in vitro</i> , Chondrosarcoma <sup>18</sup> .	Proliferation of chondrocytes from articular cartilage <sup>80</sup> .
	Increased <i>MMP9</i> and increased IL6/IL-6-STAT3 pathway in patient chondrocytes	Susceptible to osteoarthritis, increased catabolic and decreased anabolic activity in articular cartilage, increased <i>IL6</i> <sup>20</sup> .	
	Low total body bone mineral density with vertebral compression fractures	Decreased bone volume <sup>19</sup> .	Posttransplant osteoporosis in organ recipients <sup>66</sup> , reduced bone mass and osteoporosis in FK506-treated mice in mice <sup>19</sup> and rats <sup>81</sup> .
<b>B cell lymphoma and malignancies</b>	Effaced lymph node architecture, showing B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL	Effaced lymph node architecture, increased incidence of B cell malignancies, features of anaplastic and/or plasmablastic plasmacytomas, and none in <i>Nfatc2</i> <sup>+/-</sup> <sup>34</sup> .	Post-transplant lymphoproliferative disorder (PTLD) mostly in EBV <sup>+</sup> B cells <sup>82, 83</sup> , anti-apoptotic effects in Burkitt's lymphoma cell line <sup>84</sup> , increased incidence of lymphoma with topical calcineurin inhibitors <sup>85, 86</sup> .
<b>CD4<sup>+</sup> T cells impairments</b>	Higher activated (CD69 <sup>+</sup> ) T cells, accumulation of CD4 <sup>+</sup> central memory that exhibit high PD-1 expression	Age-related increase in accumulation of activated CD69 <sup>+</sup> T cells and memory T cells in secondary lymphoid organs <sup>34</sup> .	Increase in CD4 <sup>+</sup> T cell exhaustion post-kidney and post-liver transplants but not CD8 <sup>+</sup> <sup>87, 88, 89</sup> .
<b>T follicular helper cell impairment</b>	T <sub>FH</sub> cells activation is impaired and there is a lack of B cell class switching.	<i>Nfatc1/Nfatc2</i> double knockout mice: impaired T <sub>FH</sub> differentiation and function, impaired GC formation <sup>15</sup> .	Decreased T <sub>FH</sub> numbers and function, low T <sub>FH</sub> -mediated B cell differentiation in transplant patients <sup>90, 91</sup> .

708

709

710

711 **REFERENCES**

- 712 1. Vig, M. & Kinet, J.P. Calcium signaling in immune cells. *Nat Immunol* **10**, 21-27 (2009).  
713
- 714 2. Vaeth, M., Kahlfuss, S. & Feske, S. CRAC Channels and Calcium Signaling in T Cell-Mediated  
715 Immunity. *Trends Immunol* **41**, 878-901 (2020).
- 716
- 717 3. Feske, S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol* **7**, 690-702  
718 (2007).
- 719
- 720 4. Vaeth, M. & Feske, S. NFAT control of immune function: New Frontiers for an Abiding Trooper.  
721 *F1000Res* **7**, 260 (2018).
- 722
- 723 5. Macian, F. NFAT proteins: key regulators of T-cell development and function. *Nat Rev Immunol*  
724 **5**, 472-484 (2005).
- 725
- 726 6. Loh, C. *et al.* Calcineurin binds the transcription factor NFAT1 and reversibly regulates its  
727 activity. *J Biol Chem* **271**, 10884-10891 (1996).
- 728
- 729 7. Luo, C. *et al.* Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates  
730 transcription of several cytokine genes. *Mol Cell Biol* **16**, 3955-3966 (1996).
- 731
- 732 8. Luo, C. *et al.* Interaction of calcineurin with a domain of the transcription factor NFAT1 that  
733 controls nuclear import. *Proc Natl Acad Sci U S A* **93**, 8907-8912 (1996).
- 734
- 735 9. Shaw, K.T. *et al.* Immunosuppressive drugs prevent a rapid dephosphorylation of transcription  
736 factor NFAT1 in stimulated immune cells. *Proc Natl Acad Sci U S A* **92**, 11205-11209 (1995).
- 737
- 738 10. Clipstone, N.A. & Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T-  
739 lymphocyte activation. *Nature* **357**, 695-697 (1992).
- 740
- 741 11. Rao, A., Luo, C. & Hogan, P.G. Transcription factors of the NFAT family: regulation and function.  
742 *Annu Rev Immunol* **15**, 707-747 (1997).
- 743
- 744 12. Shibasaki, F., Price, E.R., Milan, D. & McKeon, F. Role of kinases and the phosphatase calcineurin  
745 in the nuclear shuttling of transcription factor NF-AT4. *Nature* **382**, 370-373 (1996).
- 746
- 747 13. Shaw, J.P. *et al.* Identification of a putative regulator of early T cell activation genes. *Science* **241**,  
748 202-205 (1988).

749

- 750 14. Hermann-Kleiter, N. & Baier, G. NFAT pulls the strings during CD4+ T helper cell effector  
751 functions. *Blood* **115**, 2989-2997 (2010).
- 752
- 753 15. Martinez, G.J. *et al.* Cutting Edge: NFAT Transcription Factors Promote the Generation of  
754 Follicular Helper T Cells in Response to Acute Viral Infection. *J Immunol* **196**, 2015-2019 (2016).
- 755
- 756 16. Peng, S.L., Gerth, A.J., Ranger, A.M. & Glimcher, L.H. NFATc1 and NFATc2 together control both  
757 T and B cell activation and differentiation. *Immunity* **14**, 13-20 (2001).
- 758
- 759 17. Zanoni, I. *et al.* CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT  
760 activation. *Nature* **460**, 264-268 (2009).
- 761
- 762 18. Ranger, A.M. *et al.* The nuclear factor of activated T cells (NFAT) transcription factor NFATp  
763 (NFATc2) is a repressor of chondrogenesis. *J Exp Med* **191**, 9-22 (2000).
- 764
- 765 19. Koga, T. *et al.* NFAT and Osterix cooperatively regulate bone formation. *Nat Med* **11**, 880-885  
766 (2005).
- 767
- 768 20. Wang, J. *et al.* Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of  
769 adult articular chondrocytes. *J Pathol* **219**, 163-172 (2009).
- 770
- 771 21. Ho, I.C., Kim, J.H., Rooney, J.W., Spiegelman, B.M. & Glimcher, L.H. A potential role for the  
772 nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis.  
773 *Proc Natl Acad Sci U S A* **95**, 15537-15541 (1998).
- 774
- 775 22. Bourajjaj, M. *et al.* NFATc2 is a necessary mediator of calcineurin-dependent cardiac  
776 hypertrophy and heart failure. *J Biol Chem* **283**, 22295-22303 (2008).
- 777
- 778 23. Jauliac, S. *et al.* The role of NFAT transcription factors in integrin-mediated carcinoma invasion.  
779 *Nat Cell Biol* **4**, 540-544 (2002).
- 780
- 781 24. Mognol, G.P., Carneiro, F.R., Robbs, B.K., Faget, D.V. & Viola, J.P. Cell cycle and apoptosis  
782 regulation by NFAT transcription factors: new roles for an old player. *Cell Death Dis* **7**, e2199  
783 (2016).
- 784
- 785 25. Casolaro, V. *et al.* Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for  
786 differential gene expression in T helper cell subsets. *Proc Natl Acad Sci U S A* **92**, 11623-11627  
787 (1995).
- 788
- 789 26. Liu, J. *et al.* Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506  
790 complexes. *Cell* **66**, 807-815 (1991).

- 791  
792 27. First, M.R. Tacrolimus based immunosuppression. *J Nephrol* **17 Suppl 8**, S25-31 (2004).  
793  
794 28. Azzi, J.R., Sayegh, M.H. & Mallat, S.G. Calcineurin inhibitors: 40 years later, can't live without. *J*  
795 *Immunol* **191**, 5785-5791 (2013).  
796  
797 29. Cury Martins, J. *et al.* Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev*,  
798 CD009864 (2015).  
799  
800 30. Safarini, O.A. & Patel, J. Calcineurin Inhibitors. *StatPearls*: Treasure Island (FL), 2021.  
801  
802 31. Lee, M. & Park, J. Regulation of NFAT activation: a potential therapeutic target for  
803 immunosuppression. *Mol Cells* **22**, 1-7 (2006).  
804  
805 32. van Kuilenburg, A.B.P. *et al.* Glutaminase Deficiency Caused by Short Tandem Repeat Expansion  
806 in GLS. *N Engl J Med* **380**, 1433-1441 (2019).  
807  
808 33. Tarailo-Graovac, M. *et al.* Exome Sequencing and the Management of Neurometabolic  
809 Disorders. *N Engl J Med* **374**, 2246-2255 (2016).  
810  
811 34. May, S.L. *et al.* Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and  
812 tumorigenesis. *PLoS One* **9**, e100629 (2014).  
813  
814 35. Lu, H.Y. *et al.* Mechanistic understanding of the combined immunodeficiency in complete  
815 human CARD11 deficiency. *J Allergy Clin Immunol* (2021).  
816  
817 36. Lu, H.Y. *et al.* The importance of functional validation after next-generation sequencing:  
818 evaluation of a novel CARD11 variant. *Pediatr Allergy Immunol* **29**, 663-668 (2018).  
819  
820 37. Fung, S.Y. *et al.* MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-kappaB Signaling  
821 and Inflammatory Responsiveness. *Front Immunol* **12**, 749794 (2021).  
822  
823 38. Kutner, R.H., Zhang, X.Y. & Reiser, J. Production, concentration and titration of pseudotyped  
824 HIV-1-based lentiviral vectors. *Nat Protoc* **4**, 495-505 (2009).  
825  
826 39. Jia, A. *et al.* Clinical IRAK4 deficiency caused by homozygosity for the novel IRAK4 (c.1049delG,  
827 p.Gly350Glufs\*15) variant. *Cold Spring Harb Mol Case Stud* **6** (2020).  
828  
829 40. Carson, R.T. & Vignali, D.A. Simultaneous quantitation of 15 cytokines using a multiplexed flow  
830 cytometric assay. *J Immunol Methods* **227**, 41-52 (1999).



- 831  
832 41. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time  
833 quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. *Methods* **25**, 402-408 (2001).
- 834  
835 42. Chen, Y., Lun, A.T. & Smyth, G.K. From reads to genes to pathways: differential expression  
836 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline.  
837 *F1000Res* **5**, 1438 (2016).
- 838  
839 43. Ritchie, M.E. *et al.* limma powers differential expression analyses for RNA-sequencing and  
840 microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 841  
842 44. Kulpa, D.A. *et al.* Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency  
843 Reversal in CD4(+) T Cells. *J Virol* **93** (2019).
- 844  
845 45. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic  
846 data across different conditions, technologies, and species. *Nat Biotechnol* **36**, 411-420 (2018).
- 847  
848 46. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional  
849 profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).
- 850  
851 47. Novershtern, N. *et al.* Densely interconnected transcriptional circuits control cell states in  
852 human hematopoiesis. *Cell* **144**, 296-309 (2011).
- 853  
854 48. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data  
855 using regularized negative binomial regression. *Genome Biol* **20**, 296 (2019).
- 856  
857 49. Robinson, M.D. & Smyth, G.K. Moderated statistical tests for assessing differences in tag  
858 abundance. *Bioinformatics* **23**, 2881-2887 (2007).
- 859  
860 50. Burrage, P.S., Mix, K.S. & Brinckerhoff, C.E. Matrix metalloproteinases: role in arthritis. *Front*  
861 *Biosci* **11**, 529-543 (2006).
- 862  
863 51. Nguyen, L., Papenhausen, P. & Shao, H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and  
864 Molecular Aspects. *Genes (Basel)* **8** (2017).
- 865  
866 52. McGettrick, A.F. & O'Neill, L.A.J. The Role of HIF in Immunity and Inflammation. *Cell Metab* **32**,  
867 524-536 (2020).
- 868  
869 53. Zhu, F., Wang, K.B. & Rui, L. STAT3 Activation and Oncogenesis in Lymphoma. *Cancers (Basel)* **12**  
870 (2019).


- 871  
872 54. Zhang, Y. *et al.* Tumor necrosis factor- $\alpha$  induced protein 8 polymorphism and risk of non-  
873 Hodgkin's lymphoma in a Chinese population: a case-control study. *PLoS One* **7**, e37846 (2012).
- 874  
875 55. Corso, J. *et al.* Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma  
876 provides insights into regulation of cell survival. *Proc Natl Acad Sci U S A* **113**, 5688-5693 (2016).
- 877  
878 56. Jasenosky, L.D. *et al.* Identification of a Distal Locus Enhancer Element That Controls Cell Type-  
879 Specific TNF and LTA Gene Expression in Human T Cells. *J Immunol* **205**, 2479-2488 (2020).
- 880  
881 57. Kuprash, D.V. *et al.* Cyclosporin A blocks the expression of lymphotoxin  $\alpha$ , but not  
882 lymphotoxin  $\beta$ , in human peripheral blood mononuclear cells. *Blood* **100**, 1721-1727 (2002).
- 883  
884 58. Xu, T., Keller, A. & Martinez, G.J. NFAT1 and NFAT2 Differentially Regulate CTL Differentiation  
885 Upon Acute Viral Infection. *Front Immunol* **10**, 184 (2019).
- 886  
887 59. Vafadari, R., Kraaijeveld, R., Weimar, W. & Baan, C.C. Tacrolimus inhibits NF- $\kappa$ B activation in  
888 peripheral human T cells. *PLoS One* **8**, e60784 (2013).
- 889  
890 60. Nassef Kadry Naguib Roufaiel, M., Wells, J.W. & Steptoe, R.J. Impaired T-Cell Function in B-Cell  
891 Lymphoma: A Direct Consequence of Events at the Immunological Synapse? *Front Immunol* **6**,  
892 258 (2015).
- 893  
894 61. Shin, D.S. *et al.* Regulatory T cells suppress CD4+ T cells through NFAT-dependent transcriptional  
895 mechanisms. *EMBO Rep* **15**, 991-999 (2014).
- 896  
897 62. Ding, B.B., Bi, E., Chen, H., Yu, J.J. & Ye, B.H. IL-21 and CD40L synergistically promote plasma cell  
898 differentiation through upregulation of Blimp-1 in human B cells. *J Immunol* **190**, 1827-1836  
899 (2013).
- 900  
901 63. Bauer, W. *et al.* Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking  
902 the transcription factor NFATc2. *Haematologica* **96**, 1580-1588 (2011).
- 903  
904 64. Xanthoudakis, S. *et al.* An enhanced immune response in mice lacking the transcription factor  
905 NFAT1. *Science* **272**, 892-895 (1996).
- 906  
907 65. Hodge, M.R. *et al.* Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient  
908 mice. *Immunity* **4**, 397-405 (1996).
- 909  
910 66. Yu, T.M. *et al.* Osteoporosis and fractures after solid organ transplantation: a nationwide  
911 population-based cohort study. *Mayo Clin Proc* **89**, 888-895 (2014).

- 912  
913 67. Teixeira, L.K. *et al.* NFAT1 transcription factor regulates cell cycle progression and cyclin E  
914 expression in B lymphocytes. *Cell Cycle* **15**, 2346-2359 (2016).
- 915  
916 68. Schmid, C.A. *et al.* DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling  
917 and tumor cell survival in diffuse large B cell lymphoma. *J Exp Med* **212**, 775-792 (2015).
- 918  
919 69. Xu-Monette, Z.Y., Zhou, J. & Young, K.H. PD-1 expression and clinical PD-1 blockade in B-cell  
920 lymphomas. *Blood* **131**, 68-83 (2018).
- 921  
922 70. Rosales, Y.M.Z. *et al.* Use of checkpoint inhibitors in gray zone lymphoma. *Hematol Oncol Stem*  
923 *Cell Ther* (2020).
- 924  
925 71. Al-Mansour, Z., Nelson, B.P. & Evens, A.M. Post-transplant lymphoproliferative disease (PTLD):  
926 risk factors, diagnosis, and current treatment strategies. *Curr Hematol Malig Rep* **8**, 173-183  
927 (2013).
- 928  
929 72. Singavi, A.K., Harrington, A.M. & Fenske, T.S. Post-transplant lymphoproliferative disorders.  
930 *Cancer Treat Res* **165**, 305-327 (2015).
- 931  
932 73. Rengarajan, J. *et al.* Sequential involvement of NFAT and Egr transcription factors in FasL  
933 regulation. *Immunity* **12**, 293-300 (2000).
- 934  
935 74. Miggelbrink, A.M. *et al.* CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?  
936 *Clin Cancer Res* **27**, 5742-5752 (2021).
- 937  
938 75. Karwot, R. *et al.* Protective role of nuclear factor of activated T cells 2 in CD8+ long-lived  
939 memory T cells in an allergy model. *J Allergy Clin Immunol* **121**, 992-999 e996 (2008).
- 940  
941 76. Kwon, H.K. *et al.* Transcription factor NFAT1 controls allergic contact hypersensitivity through  
942 regulation of activation induced cell death program. *Sci Rep* **6**, 19453 (2016).
- 943  
944 77. Kuo, P.T. *et al.* The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. *Front*  
945 *Med (Lausanne)* **5**, 271 (2018).
- 946  
947 78. Keller, H.R. *et al.* The Abundance and Availability of Cytokine Receptor IL-2Rbeta (CD122)  
948 Constrain the Lymphopenia-Induced Homeostatic Proliferation of Naive CD4 T Cells. *J Immunol*  
949 **204**, 3227-3235 (2020).
- 950  
951 79. Chan, A.Y. & Torgerson, T.R. Primary immune regulatory disorders: a growing universe of  
952 immune dysregulation. *Curr Opin Allergy Clin Immunol* **20**, 582-590 (2020).

- 953  
954 80. Kang, S.W., Kim, J. & Shin, D.Y. Inhibition of senescence and promotion of the proliferation of  
955 chondrocytes from articular cartilage by CsA and FK506 involves inhibition of p38MAPK. *Mech*  
956 *Ageing Dev* **153**, 7-13 (2016).
- 957  
958 81. Kirino, S. *et al.* Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. *J*  
959 *Bone Miner Metab* **22**, 554-560 (2004).
- 960  
961 82. Caduff, N. *et al.* Immunosuppressive FK506 treatment leads to more frequent EBV-associated  
962 lymphoproliferative disease in humanized mice. *PLoS Pathog* **16**, e1008477 (2020).
- 963  
964 83. Taylor, A.L., Marcus, R. & Bradley, J.A. Post-transplant lymphoproliferative disorders (PTLD) after  
965 solid organ transplantation. *Crit Rev Oncol Hematol* **56**, 155-167 (2005).
- 966  
967 84. Kondo, E. *et al.* NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the  
968 B cell antigen receptor. *Eur J Immunol* **33**, 1-11 (2003).
- 969  
970 85. Lam, M., Zhu, J.W., Tadrous, M. & Drucker, A.M. Association Between Topical Calcineurin  
971 Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma:  
972 A Systematic Review and Meta-analysis. *JAMA Dermatol* **157**, 549-558 (2021).
- 973  
974 86. Wu, P.C., Huang, I.H., Liu, C.W. & Huang, Y.C. Topical calcineurin inhibitors and risk of  
975 lymphoma: a systematic review and meta-analysis. *J Dtsch Dermatol Ges* **19**, 1265-1269 (2021).
- 976  
977 87. Angeletti, A., Cantarelli, C., Riella, L.V., Fribourg, M. & Cravedi, P. T Cell Exhaustion in Organ  
978 Transplantation. *Transplantation* (2021).
- 979  
980 88. Fribourg, M. *et al.* T-cell exhaustion correlates with improved outcomes in kidney transplant  
981 recipients. *Kidney Int* **96**, 436-449 (2019).
- 982  
983 89. Li, J. *et al.* Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. *Transplant*  
984 *Proc* **40**, 1495-1497 (2008).
- 985  
986 90. Zhang, K. *et al.* A pilot study on the characteristics of circulating T follicular helper cells in liver  
987 transplant recipients. *Transpl Immunol* **47**, 32-36 (2018).
- 988  
989 91. Wallin, E.F., Hill, D.L., Linterman, M.A. & Wood, K.J. The Calcineurin Inhibitor Tacrolimus  
990 Specifically Suppresses Human T Follicular Helper Cells. *Front Immunol* **9**, 1184 (2018).
- 991  
992


993

994 **Figures:**




996 **Fig. 1. Clinical phenotype of a patient with NFAT1 deficiency, joint contractures,**  
997 **and B cell malignancy. A)** X-ray demonstrating extent to which knees could be  
998 straightened documenting the fixed flexion deformity. **B)** Osteochondroma (indicated by  
999 the arrow) on the anterior aspect of the right proximal fibula. **C)** Hematoxylin and eosin  
1000 (H&E) stain, and CD20, CD21, CD30, BCL2, and BCL6 immunostain of a patient lymph  
1001 node biopsy. Scale bar for H&E, CD20, CD30, BCL6, and BCL2 is 50 $\mu$ m and for CD21  
1002 is 3mm. **D)** Family pedigree. Half-filled symbols=heterozygous unaffected individuals,  
1003 filled symbols=homozygous affected individual, arrow=proband, question  
1004 marks=ungenotyped. **E)** Sanger sequencing of DNA extracted from whole blood of the  
1005 patient, family members, and a healthy control. Site of four base pair deletion is  
1006 indicated. **F)** Schematic illustrating the protein domains of NFAT1. Location of variant  
1007 shown in red. Affected region was aligned to other species. Asterisks indicate full  
1008 conservation. **G)** Schematic illustrating ionomycin-induced activation of calcineurin and  
1009 NFAT1. **H)** *NFATC2* transcript abundance relative to  $\beta$ -actin (*ACTB*) in the patient (II-1),  
1010 a heterozygous control (II-2), and a healthy control (HC) determined by qPCR. Red  
1011 circles=II-1, blue circles=II-2, green circles=HC. \*\*  $p < 0.01$ , \*\*\*\* $p < 0.0001$ . One-way  
1012 ANOVA and Tukey's post-hoc test. **I)** Immunoblot of patient (II-1), heterozygous control  
1013 (II-2), and control-derived LCLs using an N-terminal NFAT1 antibody before and after  
1014 10 min ionomycin stimulation with or without FK506 treatment. N = 3.

1015






1017 **Fig. 2. NFAT1 deficiency in chondrocytes leads to an increased pro-survival and**  
1018 **proinflammatory phenotype. A)** Immunoblot of empty vector (EV)- and WT *NFATC2*-  
1019 transduced patient chondrocytes before and after 15min phorbol 12-myristate 13-  
1020 acetate/ionomycin (P/I) stimulation, 20ng/mL IL-1 $\beta$  stimulation, or no treatment. n=3. **B)-**  
1021 **D)** RNA-Seq carried out on EV- or WT *NFATC2*-transduced patient chondrocytes  
1022 unstimulated or stimulated 24h with P/I or 20ng/mL IL-1 $\beta$ . **B)** Venn diagram of  
1023 significantly (FDR<0.05) **(i)** upregulated and **(ii)** downregulated genes in EV-transduced  
1024 patient chondrocytes compared to WT *NFATC2*-transduced chondrocytes. **C)** Heatmap  
1025 of top genes that meet a FDR<0.025 cutoff between EV and WT *NFATC2*-transduced  
1026 patient chondrocytes. **D)** Heatmap of sample level enrichment scores (SLEA) scores  
1027 with normalized enrichment scores (NES), p-val, and q-values for each pathway  
1028 determined by gene set enrichment analysis (GSEA). Min and max refer to the row-  
1029 normalized minimum and maximum for each pathway. **E)** Measurement of percent cell  
1030 death in chondrocytes over 12 days by quantifying lactate dehydrogenase in  
1031 supernatants. \*p<0.05, \*\*\*p<0.001 Two-way ANOVA, Dunnett's post-hoc test. **F)** ELISA  
1032 detection of IL-6 production from the supernatants of chondrocytes in different  
1033 conditions. \*p<0.05, \*\*\*p<0.001 Mann-Whitney U-test.



1035 **Fig. 3. NFAT1 deficiency leads to accumulation of hyperproliferative naïve B cells. A-C)** Single cell RNA-  
1036 Sequencing of peripheral blood mononuclear cells from the patient (II-1), heterozygous controls (n=3), and a healthy  
1037 control (n=2) stimulated with P/I for 4h. **A)** Uniform manifold approximation and projection (UMAP) visualization of  
1038 stimulated cell subsets. Cell labels indicated on right. **B)** Volcano plot showing differential gene expression in naïve B cells  
1039 between patient and 5 healthy controls. Dark colors=significance, dim colors=nominal significance but not after adjusted  
1040 p-value, grey colors=not significant. **C)** Violin plots of significantly differentially expressed genes of interest in naïve B cells  
1041 comparing patient and healthy controls. **D)** Expression of NFAT1 in patient and control naïve B cells. Mean fluorescence  
1042 intensities (MFIs) are indicated. **E)** Frequency of IgM<sup>++</sup>CD38<sup>++</sup> transitional B cells in the patient (II-1) and heterozygous  
1043 (n=4) and healthy controls (n=8). **F)** Quantification of **E)**. **G)** Frequency of IgD<sup>+</sup>CD27<sup>-</sup> naïve (N) and IgD<sup>-</sup>CD27<sup>+</sup> memory  
1044 (M) B cells in the patient and one representative control. Schematic of quadrants that correspond to each cell population  
1045 and frequency shown top right. **H,I)** Quantification of **G)**. **J)** Frequency of CD27<sup>+</sup>CD38<sup>+</sup> plasmablasts in mature CD19<sup>+</sup> B  
1046 cells. **K)** IgD and IgM expression in each individual. MFIs are indicated. **I)** Frequency of Ki67<sup>+</sup> naïve B cells in the patient  
1047 and a representative control. **M)** Quantification of **I)**. **N)** Frequency of TNF- $\alpha$ <sup>+</sup> naïve B cells in the patient and a  
1048 representative control. **O)** Quantification of **n)**. **P-Q)** Isolated naïve B cells from patient, heterozygous (n=1), and healthy  
1049 controls (n=6) expanded for 6 days. **P)** Frequency of class-switched memory B cells and **Q)** plasmablasts before and after  
1050 expansion. \*p<0.05, \*\*p<0.01. One-way ANOVA and Tukey's posthoc test. Green circles=healthy control, blue circle=II-2,  
1051 blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.



1053 **Fig. 4. NFAT1 deficiency impairs memory CD8<sup>+</sup> T cell function. A)** Volcano plot  
1054 showing differential gene expression in CD8<sup>+</sup> memory T cells between patient and 5  
1055 healthy controls (3 heterozygous controls, and 2 healthy controls). **B)** Violin plots of  
1056 significantly differentially expressed genes of interest in CD8<sup>+</sup> memory T cells in patient  
1057 and healthy controls. **C)** Frequency of CD8<sup>+</sup> T cell subsets in the patient and a  
1058 representative control, including CD45RA<sup>+</sup>CD27<sup>-</sup> TEMRA, CD45RA<sup>+</sup>CD27<sup>+</sup> Naïve (N),  
1059 CD45RA<sup>-</sup>CD27<sup>-</sup> effector memory (EM), CD45RA<sup>-</sup>CD27<sup>+</sup> central memory (CM).  
1060 Quadrants corresponding to each subset shown top right. **D)** Quantification of **C)**. **E)**  
1061 Expression of NFAT1 in patient and control naïve and memory CD8<sup>+</sup> T cells. Mean  
1062 fluorescence intensities (MFIs) are indicated. **F)** TNF- $\alpha$  and IFN- $\gamma$  expression in memory  
1063 CD8<sup>+</sup> T cells in the patient and a control. **G, H)** Quantification of **F)**. **I)** CD69 and PD-1  
1064 expression in patient and control memory CD8<sup>+</sup> T cells after 4h of P/I stimulation. MFIs  
1065 are indicated. \* $p < 0.05$ , \*\*\*\* $p < 0.0001$ . One-way ANOVA and Tukey's post-hoc test.  
1066 Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted  
1067 triangle=I-1, blue square=II-3, red diamond=II-1.

1068

1069

1070

1071

1072


1073

1074


1075

1076

1077



1079 **Fig. 5. Patient CD4<sup>+</sup> T cells are exhausted. A)** Volcano plot showing differential gene expression in CD4<sup>+</sup> memory T  
1080 cells between patient and 5 healthy controls. **B)** Violin plots of significantly differentially expressed genes of interest in  
1081 CD4<sup>+</sup> memory T cells in patient and healthy controls. **C)** Frequency of CD8<sup>+</sup> T cell subsets in the patient and a  
1082 representative control, including CD45RA<sup>+</sup>CD27<sup>-</sup> TEMRA, CD45RA<sup>+</sup>CD27<sup>+</sup> Naïve (N), CD45RA<sup>-</sup>CD27<sup>-</sup> effector memory  
1083 (EM), CD45RA<sup>-</sup>CD27<sup>+</sup> central memory (CM). Quadrants corresponding to each subset shown top right. **D)** Quantification  
1084 of **C)**. **E)** Expression of NFAT1 in patient and control naïve and memory CD4<sup>+</sup> T cells. Mean fluorescence intensities are  
1085 indicated. **F)** Frequency of T<sub>H</sub>1 (IFN-γ<sup>+</sup>IL-17A<sup>-</sup>), T<sub>H</sub>17 (IL-17A<sup>+</sup>IFN-γ<sup>+</sup>) cells in memory CD4<sup>+</sup> T cells of the patient and a  
1086 representative control. **G-H)** Quantification of **F)**. **I)** Frequency of T<sub>H</sub>2 (IL-4<sup>+</sup>IL-21<sup>-</sup>) and T<sub>FH</sub> (IL-21<sup>+</sup>IL-4<sup>-</sup>) cells in memory  
1087 CD4<sup>+</sup> T cells of the patient and a representative control. **J-K)** Quantification of **I)**. **L)** Frequency of TNF-α<sup>+</sup> and IL-2<sup>+</sup> CD4<sup>+</sup>  
1088 memory T cells in the patient and a representative control. **M,N)** Quantification of **L)**. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001,  
1089 \*\*\*\*p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=IL-2, blue upright  
1090 triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.






1092 **Fig. 6. NFAT1 deficiency impairs T<sub>FH</sub> function. A)** Expression of activation markers in  
1093 CD4<sup>+</sup> memory T cells after P/I treatment, including CD69, PD-1, CD40L, CD25 and  
1094 ICOS. Mean fluorescence intensities (MFIs) are indicated. **B)** Frequency of circulating  
1095 T<sub>FH</sub> (cT<sub>FH</sub>) cells in PD-1<sup>+</sup> memory CD4<sup>+</sup> T cells in the patient and a representative  
1096 control. **C)** Quantification of **B)**. **D)** CD40L and IL-21 expression in patient and control  
1097 cT<sub>FH</sub> cells after 4h P/I stimulation. **E,F)** Quantification of **D)**. **G)** Frequency of CD40L<sup>+</sup>  
1098 and TNF-α<sup>+</sup> GFP<sup>+</sup> CD4<sup>+</sup> patient or control memory T cells after 4h P/I stimulation of EV  
1099 or WT *NFATC2* transduction. **H,I)** Quantification of **G)**. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001,  
1100 \*\*\*\*p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy  
1101 control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue  
1102 square=II-3, red diamond=II-1.

1103


1104 **Supplementary figures:**



1105


1106 **Supp Fig. 1. Extended B cell phenotyping. A)** Gating strategy for transitional B cells  
1107 and plasmablasts in mature CD19<sup>+</sup> B cells. **B,C)** Quantification of IgD and IgM MFI in  
1108 patient and control naïve B cells. **D)** Naïve B cells were isolated from patient and a  
1109 control and expanded *in vitro*. Frequency of CD27<sup>+</sup>CD38<sup>-</sup> memory B cells was  
1110 enumerated at Day 0 (Non-expanded) and Day 6 (Expanded). \*\*p<0.01. One-way  
1111 ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue  
1112 upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.

1113




1114

1115 **Supp Fig. 2. Extended CD8<sup>+</sup> T cell phenotyping.** **A)** Frequency of IL-2<sup>+</sup> naïve CD8<sup>+</sup> T  
 1116 cells in the patient and a representative control. **B)** Quantification of **A)**. **C)** Frequency of  
 1117 IL-2<sup>+</sup> memory CD8<sup>+</sup> T cells in the patient and a representative control. **D)** Quantification  
 1118 of **C)**. **E)** CD40L expression in memory CD8<sup>+</sup> T cells. Mean fluorescence intensities are  
 1119 indicated. **F-H)** Quantification of **F)** CD40L<sup>+</sup>, **G)** CD69<sup>+</sup>, and **H)** PD-1<sup>+</sup> CD8<sup>+</sup> memory T  
 1120 cells. \*p<0.05, \*\*p<0.01. One-way ANOVA and Tukey's post-hoc test. Green  
 1121 circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted  
 1122 triangle=I-1, blue square=II-3, red diamond=II-1.




1124 **Supp Fig. 3. Extended CD4<sup>+</sup> T cell immunophenotyping.** **A)** Frequency of IFN- $\gamma$ <sup>+</sup> and IL-17A<sup>+</sup> naïve CD4<sup>+</sup> T cells in the  
1125 patient and a representative control. **B,C)** Quantification of **A).** **D)** Frequency of IL-21<sup>+</sup> and IL-4<sup>+</sup> naïve CD4<sup>+</sup> T cells in the  
1126 patient and a representative control. **E,F)** Quantification of **D).** **G)** Frequency of TNF- $\alpha$ <sup>+</sup> and IL-2<sup>+</sup> naïve CD4<sup>+</sup> T cells in the  
1127 patient and a representative control. **H,I)** Quantification of **G).** **J)** naïve CD4<sup>+</sup> T cell expression of activation markers,  
1128 including PD-1, CD40L, CD69, CD25, and ICOS. Mean fluorescence intensities (MFIs) are indicated. **K-O)** Frequency of  
1129 same activation markers as in **J).** **P-T)** Quantification of frequencies and MFIs of CD4<sup>+</sup> memory T cell activation markers,  
1130 including PD-1, CD40L, CD69, CD25 and ICOS. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001. One-way ANOVA and  
1131 Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1,  
1132 blue square=II-3, red diamond=II-1.



1133

1134 **Supp Fig. 4. CD4<sup>+</sup> T cell gating strategies. A)** Gating strategy for circulating T  
 1135 follicular helper cells (T<sub>FH</sub>) defined as CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>. **B)**  
 1136 Gating strategy for identifying WT *NFATC2*-transduced CD4<sup>+</sup> memory T cells.





1138 **Supp Fig. 5. Patient T regulatory cell phenotype. A)** Gating strategy for naïve and activated T regulatory cells (Treg)  
1139 defined as CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD25<sup>+</sup>CD127<sup>-</sup>FOXP3<sup>+</sup> and CD45RA<sup>+/-</sup>. **B,C)** Frequency of **B)** naïve and **C)** memory Tregs. **D)**  
1140 Frequency of TNF- $\alpha$ <sup>+</sup> and IFN- $\gamma$ <sup>+</sup> activated Tregs in the patient and a representative control. **E,F)** Quantification of **D)**. **G)**  
1141 Frequency of IL-2<sup>+</sup> activated Tregs in the patient and a representative control. **H)** Quantification of **G)**. **I-O)** Quantification  
1142 of Treg stability markers **I)** FOXP3 and **J)** Helios, and activation markers, **K)** CD25, **L)** CD69, **M)** CTLA4, **N)** ICOS, and **O)**  
1143 PD-1 in activated Tregs. \*\*p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, red  
1144 diamond=IL-1.

1145 **Supplementary Tables:**

1146

1147 **Supplementary Table 1: Gait and physical assessment in the patient**

	<b>Gait Assessment</b>	<b>Physical Assessment</b>
Hip	Anterior pelvic tilt with adduction of thighs	Hip flexion contractures bilaterally, -20°
	Decreased dynamic hip range of motion	Decreased hip abduction, 5° right, 10° left
	Decreased hip extension in terminal stance	Decreased hip external rotation, neutral bilaterally
	Hip flexion contractures	Decreased hip internal rotation, 25° right, 10° left
		Positive Thomas test bilaterally
Knee		Positive Ober test bilaterally
	Knee flexion contractures bilaterally with decreased popliteal angles	Knee flexion contractures bilaterally, -45° right, -30° left
	Increased knee flexion throughout stance	Popliteal angles; -70° right, -50° left
	Incomplete knee flexion throughout terminal swing	Total range of motion for his left knee is approximately 30 -40°, and total range of motion for his right knee is approximately 90°
Ankle	Decreased ankle dorsiflexion bilaterally	Decreased ankle dorsiflexion bilaterally; -10° with knee flexed, -20° with knee extended
	Sagittal joint powers are decreased at the ankle, left more than right	
	Absent first rocker bilaterally with abbreviated left second ankle rocker and aborted right second ankle rockers	
Foot	Neutral foot progression angle on the frontal plane	
	Mild left hind foot varus with forefoot pronation	
	Bilateral forefoot internal rotation	
	Pedobarography shows absent hindfoot pressures bilaterally	
Upper limbs	Decreased arm swing	Very limited flexion and extension of both thumb MCPs and both wrists
		limited extension, internal and

		external rotation of his shoulders, as well as limited lateral flexion of the cervical spine
Stride	Functional Mobility Scale (FMS), Ebrahim receives a score of 6 at 5 metres, 6 at 50 metres, and 6 at 500 metres	Demonstrates toe walking, worse on the right than on the left
	Decreased step and stride lengths	When he gets from a sitting to standing position, he relies significantly on supports due to his contractures in his knees
	Mildly decreased velocity	
	Mild increased cadence	

1148

1149

1150

1151 **Supplementary Table 2:** Clinical Flow Cytometry for determination of T cell and B cell  
 1152 subset proportions in the patient along with reference intervals

	<b>Patient Results</b>		<b>Age-Specific Reference Interval</b>
<b>Lymphocyte T and B Cell Panel</b>			
CD3 Cells	1.51	10 <sup>9</sup> /L	0.70-2.10
CD3 <sup>+</sup> CD4 <sup>+</sup> Cells	0.74	10 <sup>9</sup> /L	0.30-1.40
CD3 <sup>+</sup> CD8 <sup>+</sup> Cells	0.70	10 <sup>9</sup> /L	0.20-0.90
CD4:CD8 Ratio	1.05		1.00-3.60
CD19 <sup>+</sup> Cells	0.14	10 <sup>9</sup> /L	0.10-0.50
CD3 <sup>-</sup> CD56 <sup>+</sup> Cells	0.10	10 <sup>9</sup> /L	
<b>T-Cell Naïve &amp; Memory &amp; Effector (CD27 and CD45RA) Subsets Panel</b>			
CD4 <sup>+</sup> Naïve T-Cells (CD45RA <sup>+</sup> CCR7 <sup>+</sup> )	% of CD4 <sup>+</sup> T Cells	15.8	7.2-68.9
CD4 <sup>+</sup> Central Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>+</sup> )	% of CD4 <sup>+</sup> T Cells	<b>69.9</b>	15.0-64.3
CD4 <sup>+</sup> Effector Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>-</sup> )	% of CD4 <sup>+</sup> T Cells	13.6	4.9-43.6
CD4 <sup>+</sup> TEMRA T-Cells (CD45RA <sup>+</sup> CCR7 <sup>-</sup> )	% of CD4 <sup>+</sup> T Cells	0.7	<11.7
CD4 <sup>+</sup> CD57 <sup>+</sup> Cells	% of CD4 <sup>+</sup> T Cells	0.9	0.6-30.4
CD4 <sup>+</sup> PD1 <sup>+</sup> Cells	% of CD4 <sup>+</sup> T Cells	<b>64.8</b>	1.7-21.5
CD8 <sup>+</sup> Naïve T-Cells (CD45RA <sup>+</sup> CCR7 <sup>+</sup> )	% of CD8 <sup>+</sup> T Cells	20.5	2.6-72.4
CD8 <sup>+</sup> Central Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>+</sup> )	% of CD8 <sup>+</sup> T Cells	14.1	2.7-36.2
CD8 <sup>+</sup> Effector Memory T-Cells (CD45RA <sup>-</sup> CCR7 <sup>-</sup> )	% of CD8 <sup>+</sup> T Cells	27.8	4.7-60.1

CD8 <sup>+</sup> TEMRA T-Cells (CD45RA <sup>+</sup> CCR7 <sup>-</sup> )	% of CD8 <sup>+</sup> T Cells	37.6	1.6-62.0
CD8 <sup>+</sup> CD57 <sup>+</sup> Cells	% of CD8 <sup>+</sup> T Cells	51.2	4.6-59.6
CD8 <sup>+</sup> PD1 <sup>+</sup> Cells	% of CD8 <sup>+</sup> T Cells	20.8	5.2-63.4
<b>B-Cell Memory Subsets Panel</b>			
Switched Memory B-Cells (CD27 <sup>+</sup> IgD <sup>-</sup> IgM <sup>-</sup> )	% of B Cells	<b>0.2</b>	4.6-35.5
Unswitched Memory B-Cells (CD27 <sup>+</sup> IgM <sup>+</sup> )	% of B Cells	4.6	1.9-23.7
Naïve B-Cells (CD27 <sup>-</sup> IgD <sup>+</sup> )	% of B Cells	<b>93.7</b>	17.9-75.1
Transitional B-Cells (CD27 <sup>-</sup> IgM <sup>+</sup> CD24 <sup>hi</sup> CD38 <sup>hi</sup> )	% of B Cells	<b>15.7</b>	0.1-6.3
CD21 <sup>low</sup> B Cells	% of B Cells	13.3	1.9-19.3

1153

1154